WO2004092126A2 - Process and intermediates for the preparation of pyrrolidine carboxylic acids - Google Patents

Process and intermediates for the preparation of pyrrolidine carboxylic acids Download PDF

Info

Publication number
WO2004092126A2
WO2004092126A2 PCT/US2004/011253 US2004011253W WO2004092126A2 WO 2004092126 A2 WO2004092126 A2 WO 2004092126A2 US 2004011253 W US2004011253 W US 2004011253W WO 2004092126 A2 WO2004092126 A2 WO 2004092126A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
phenyl
heteroaryl
formula
Prior art date
Application number
PCT/US2004/011253
Other languages
French (fr)
Other versions
WO2004092126A3 (en
WO2004092126B1 (en
Inventor
Raymond Cvetovich
John Y. Chung
Joseph S. Amato
Lisa Dimichele
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to EP04750027A priority Critical patent/EP1615882A2/en
Priority to CA002521487A priority patent/CA2521487A1/en
Priority to JP2006509940A priority patent/JP2006523700A/en
Priority to US10/550,640 priority patent/US20060199958A1/en
Publication of WO2004092126A2 publication Critical patent/WO2004092126A2/en
Publication of WO2004092126A3 publication Critical patent/WO2004092126A3/en
Publication of WO2004092126B1 publication Critical patent/WO2004092126B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention provides a process for the preparation of pyrrolidine carboxylic acids of general formula (I).
  • the present invention also provides intermediates useful in the disclosed process.
  • the compounds of formula (I) are intermediates useful for the preparation of the pyrrolidine compounds of the general formula (II), wherein R2 is phenyl, unsubstituted or substituted with one to three R3 groups, r is 1 and s is 1.
  • the compounds of formula (II), along with their use as melanocortin receptor agonists were disclosed in WO 02/068387 (published on September 6, 2002), and WO 02/068388 (published on September 6, 2002).
  • the compounds of formula (II) are also useful as agents for the treatment, control or prevention of diseases, disorders or conditions responsive to the activation of one or more of the melanocortin receptors including, but are not limited to, MC-1, MC-2, MC-3, MC-4, or MC-5.
  • Such diseases, disorders or conditions include, but are not limited to, obesity, diabetes mellitus, hypertension, hyperlipidemia, osteoarthiitis, cancer, gall bladder disease, sleep apnea, depression, anxiety, compulsion, neuroses, insomnia/sleep disorder, substance abuse, pain, male and female sexual dysfunction, fever, inflammation, immune modulation, rheumatoid arthritis, skin tanning, acne and other skin disorders, neuroprotective and cognitive and memory enhancement including the treatment of Alzheimer' s disease.
  • Some compounds encompassed by formula (II) show highly selective affinity for the melanocortin-4 receptor (MC-4R) relative to MC-IR, MC-2R, MC-3R, and MC-5R, which makes them especially useful in the prevention and treatment of obesity, as well as male and/or female sexual dysfunction, including erectile dysfunction.
  • MC-4R melanocortin-4 receptor
  • MC-5R MC-IR, MC-2R, MC-3R, and MC-5R
  • the present invention is directed to an efficient chiral synthesis that produces a pyrrolidine acid of structural formula (I) in a higher yield and utilizes less expensive chemical reagents.
  • the synthetic sequence comprises 5 steps with an overall yield of about 71% and a chiral purity of >99.9 % ee of the pyrrolidine acid without the use of chromatography.
  • This invention is concerned with a process for preparing compounds of structural formula (I) and certain useful intermediates obtained during that process.
  • the process involves the chiral reduction of the halogenated ketone (IV) to form a halogenated alcohol (V).
  • the halogenated alcohol (V) is then converted to the amino alcohol (VII), via the epoxide intermediate (VI), by treatment with a base and subsequent treatment with a primary amine.
  • the alcohol of compound (VIII) is then converted to a leaving group (shown as -OZ in intermediate LX) by treatment with an alcohol activating reagent, such as C1P0(0R6)2, C1P0(N(R6)2)2, MSCI, Ms2 ⁇ , TsCl or Ts2 ⁇ .
  • an alcohol activating reagent such as C1P0(0R6)2, C1P0(N(R6)2)2, MSCI, Ms2 ⁇ , TsCl or Ts2 ⁇ .
  • the present invention provides a process for the preparation of compounds of structural formula (I): (D
  • Rl is selected from the group consisting of (1) hydrogen,
  • R2 is selected from the group consisting of
  • heteroaryl is selected from the group consisting of (1) pyridinyl, (2) furyl,
  • each R3 is independently selected from the group consisting of
  • OCH2CF3 in which heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, oxo, C ⁇ _4 alkyl, trifluoromethyl, and C ⁇ _4 alkoxy; and wherein any methylene (CH2) carbon atom in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cl .4 alkyl; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
  • each R is independently selected from the group consisting of
  • alkyl, phenyl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with one to three groups independently selected from halogen, Ci-4 alkyl, hydroxy, and C1-4 alkoxy; or two R4 groups together with the atom to which they are attached form a 4- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and NC ⁇ .4 alkyl; and n is 0, 1, 2, 3 or 4;
  • Rl and R2 are as defined above, by treating an alcohol of structural formula (V), wherein X is chloride or bromide and R2 is as defined above,
  • R2 is phenyl or thienyl optionally substituted with one to three groups independently selected from R3.
  • R2 is phenyl optionally substituted with one to three groups independently selected fromR3.
  • Li a subclass of this class, R2 is selected from the group of phenyl; ortho, p ra-difluorophenyl; and /r ⁇ r ⁇ -methoxyphenyl. In a subclass of this subclass, R is ortho, pora-difluorophenyl.
  • R3 is selected from the group consisting of halogen, -CF 3 , and OR4.
  • R3 is selected from the group consisting of fluoride, bromide, chloride, -CF , and -OC ⁇ _6 alkyl.
  • R3 is selected from fluoride, bromide, -CF , and -OCH3.
  • n is 0, 1 or 2. In a class of this embodiment n is 0 or 1. In a subclass of this embodiment, n is 0. In another embodiment of the present invention, the reducing agent used to treat the compound of formula (IV) of step (a) is (+)-DIP chloride.
  • the compound of formula (IV) of step (a) is treated with a reducing agent in the presence of a catalyst.
  • the reducing agent is selected from the group consisting of borane-N,N-diethyl aniline, borane-THF, and borane-dimethylsulfide.
  • the reducing agent is borane-N,N-diethyl aniline.
  • the catalyst is selected from the group consisting of (S)-CBS and (S)-2-methyl CBS oxazaborolidine.
  • the catalyst is (S)-2-methyl CBS oxazaborolidine.
  • alcohol of formula (V) is treated with an amine of general formula R NH2, wherein Rl is selected from the group consisting of hydrogen,
  • Rl is tert-butyl or -CH2-phenyl. In a subclass of this class, Rl is tert-butyl.
  • the alcohol of formula (V) is treated with a base selected from the group consisting of NaOH, LiOH, KOH.
  • the base is NaOH.
  • the alcohol of formula (V) is treated in a solvent selected from methanol or ethanol.
  • the solvent is methanol.
  • the solvent is refmxing methanol.
  • the amino alcohol of structural formula (VII) is isolated by recrystallization from heptane or hexane.
  • the solvent is heptane.
  • the compound of formula (XI) is the compound wherein Y is CN. In another embodiment of the present invention, the compound of formula (XI) is the compound wherein Y is -C ⁇ 2R ⁇ , wherein 5 is C1.4 alkyl. In a class of this embodiment Y is -CO2CH3, -C ⁇ 2CH2CH 3 , or
  • Y is -CO2CH2CH3, or -C ⁇ 2CH2CH2CH2CH 3 .
  • the compound of formula (VIE) is formed by heating the mixture to reflux.
  • the compound of formula (VHl) is formed by adding ethanol, formamide or a mixture thereof.
  • the compound of formula (VIU) is formed by adding a 1: 1 mixture of ethanol: formamide.
  • the compound of formula (VD3) is isolated by recrystallizing from heptane or hexane.
  • the compound of formula (VIE) is treated with an alcohol activating reagent selected from the group consisting of C1P0(0R6)2, C1P0(N(R6)2)2, MsCl, Ms2 ⁇ , TsCl, and Ts2 ⁇ , wherein R6 is C1.4 alkyl or phenyl.
  • the alcohol activating reagent is chlorodiethyl phosphate.
  • the compound of formula (VHl) is treated with a base selected from the group consisting of lithium hexamethyldisilazide, sodium hexamethyl disilazide, and potassium hexamethyldisilazide.
  • the base is lithium hexamethyl disilazide.
  • the compound of formula (VIU) is treated at a temperature of about -30 to about + 10 C. In a class of this embodiment, the temperature is about -15 C.
  • the pyrrolidine compound of formula (X) is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH.
  • a base selected from the group consisting of NaOH, LiOH and KOH.
  • the base is NaOH.
  • the base is aqueous NaOH.
  • the pyrrolidine compound of formula (X) is hydrolyzed in a solvent selected from the group consisting of methanol, ethanol, and isopropanol. h a class of this embodiment, the solvent is ethanol.
  • the product of step (f) is isolated by forming a zwitterion of the trans pyrrolidine acid of structural formula (I)
  • the zwitterion of the pyrrolidine acid of formula (I) is formed at the isoelectric pH using an acid or a base, h one subclass of this class, the acid is selected from sulfuric acid or hydrochloric acid. In a subclass ofthis subclass, the acid is sulfuric acid. In another subclass ofthis class, the isoelectric pH is about 6 and a stoichiometric amount of acid is added.
  • the zwitterion of the pyrrolidine acid of formula (I) is recrystallized from a solvent selected from the group consisting of ethanol, isopropyl alcohol, methyl tert-butyl ether or a mixture thereof.
  • the solvent is a mixture of isopropyl alcohol and methyl tert-butyl ether.
  • the solvent is 1:3 isopropyl alcohoLmethyl tert-butyl ether.
  • the present invention also provides a process for the preparation of compounds of structural formula (I):
  • Rl is selected from the group consisting of
  • R is selected from the group consisting of (1) Ci-4 alkyl, (2) -(CH2)n-cycloalkyl,
  • heteroaryl is selected from the group consisting of
  • each R3 is independently selected from the group consisting of
  • OCH 2 CF 3 in which heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, oxo, Ci-4 alkyl, trifluoromethyl, and Ci-4 alkoxy; and wherein any methylene (CH 2 ) carbon atom in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C ⁇ _4 alkyl; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
  • each R4 is independently selected from the group consisting of
  • alkyl, phenyl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with one to three groups independently selected from halogen, Ci-4 alkyl, hydroxy, and Ci-4 alkoxy; or two R4 groups together with the atom to which they are attached form a 4- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and NCi-4 alkyl; and n is 0, 1, 2, 3 or 4;
  • the pyrrolidine compound of formula (X) is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH.
  • the base is NaOH.
  • the base is aqueous NaOH.
  • the pyrrolidine compound of formula (X) is hydrolyzed in a solvent selected from the group consisting of methanol, ethanol, and isopropanol. In a class of this embodiment, the solvent is ethanol.
  • the present invention also provides a process for the preparation of compounds of structural formula (XLX):
  • Rl is selected from the group consisting of (1) hydrogen, (2) amidino,
  • each R3 is independently selected from the group consisting of
  • OCH 2 CF 3 in which heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, oxo, C ⁇ _4 alkyl, trifluoromethyl, and Ci-4 alkoxy; and wherein any methylene (CH2) carbon atom in R is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C ⁇ _4 alkyl; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
  • heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected
  • each R4 is independently selected from the group consisting of
  • alkyl, phenyl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with one to three groups independently selected from halogen, Ci-4 alkyl, hydroxy, and Ci-4 alkoxy; or two R 4 groups together with the atom to which they are attached form a 4 - to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and NCi .4 alkyl; and n is 0, 1, 2, 3, or 4;
  • X is bromide or chloride, and R is as defined above, with a reducing agent, and isolating the resulting product;
  • X is chloride or bromide and R3 are as defined above, with an amine of general formula RINH2, wherein R is as defined above, and a base in a solvent, and isolating the resulting product;
  • Ci -4 alkyl, and R and R3 are as defined above,
  • Y is -CN or -C ⁇ 2R ⁇
  • R5 is Ci_4 alkyl, and isolating the resulting product
  • 3 is selected from the group consisting of halogen, -CF 3 , and OR4.
  • R3 is selected from the group consisting of fluoride, bromide, chloride, -CF3, and -OC ⁇ -6 alkyl. In a subclass ofthis class, R3 is selected from fluoride, bromide, CF3, and -OCH3.
  • the reducing agent used to treat the compound of formula (XII) of step (a) is (+)-DIP chloride. In another embodiment of the present invention, the compound of formula (XII) of step (a) is treated with a reducing agent in the presence of a catalyst.
  • the reducing agent is selected from the group consisting of borane-N,N-diethyl aniline, borane-THF, and borane-dimethylsulfide.
  • the reducing agent is borane-N,N-diethyl aniline.
  • the catalyst is selected from the group consisting of (S)-CBS and (S)-2-methyl CBS oxazaborolidine.
  • the catalyst is (S)-2-methyl CBS oxazaborolidine.
  • alcohol of formula (Xlfl) is treated with an amine of general formula R H2, wherein Rl is selected from the group consisting of hydrogen, -(CH2)nPhenyl, or Ci- ⁇ alkyl.
  • Rl is tert-butyl or -CH2-phenyl.
  • Rl is tert-butyl.
  • the alcohol of formula (Xfll) is treated with a base selected from the group consisting of NaOH, LiOH, KOH.
  • the base is NaOH.
  • the alcohol of formula (XIII) is treated in a solvent selected from methanol or ethanol.
  • the solvent is methanol.
  • the solvent is refluxing methanol.
  • the amino alcohol of structural formula (XV) is isolated by recrystallization from heptane or hexane.
  • the solvent is heptane.
  • the compound of formula (XI) is the compound wherein Y is CN.
  • the compound of formula (XI) is the compound wherein Y is -C ⁇ 2R ⁇ , wherein R ⁇ is Ci-4 alkyl.
  • Y is -CO2CH3, -C ⁇ 2CH2CH 3 , or -C ⁇ 2CH2CH2CH2CH 3 .
  • Y is -C ⁇ 2CH2CH 3 , or -C ⁇ 2CH2CH2CH2CH2CH.
  • the compound of structural formula (XVI) is formed by heating the mixture to reflux.
  • the compound of structural formula (XVI) is formed by adding ethanol, formamide or a mixture thereof.
  • the compound of structural formula (XVI) is formed by adding a 1:1 mixture of ethanol:formamide.
  • the compound of structural formula (XVI) is isolated by recrystallizing from heptane or hexane.
  • the compound of structural formula (XVI) is treated with an alcohol activating reagent selected from the group consisting of C1P0(0R6)2, ClPO(N(R6)2)2, MsCl, Ms2 ⁇ , TsCl, and Ts2 ⁇ , wherein R 6 is C1-4 alkyl or phenyl.
  • the alcohol activating reagent is chlorodiethyl phosphate.
  • the compound of structural formula (XVI) is treated with a base selected from the group consisting of lithium hexamethyldisilazide, sodium hexamethyl disilazide, and potassium hexamethyldisilazide. In a class of this embodiment, the base is lithium hexamethyl disilazide.
  • the compound of structural formula (XVT) is treated at a temperature of about -30 to about +10 C. In a class of this embodiment, the temperature is about -15 C.
  • the pyrrolidine compound of formula (XVi ⁇ ) is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH. In one class ofthis embodiment, the base is NaOH. hi a subclass ofthis class, the base is aqueous NaOH.
  • the pyrrolidine compound of formula (XVT) is treated at a temperature of about -30 to about +10 C. In a class of this embodiment, the temperature is about -15 C.
  • the pyrrolidine compound of formula (XVi ⁇ ) is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH. In one class ofthis embodiment, the base is NaOH. hi a subclass ofthis class, the base is aqueous NaOH.
  • XVIH is hydrolyzed in a solvent selected from the group consisting of methanol, ethanol, and isopropanol. h a class of this embodiment, the solvent is ethanol.
  • step (f) is isolated by forming a zwitterion of the trans pyrrolidine acid of structural formula (XLX)
  • the zwitterion of the pyrrolidine acid of formula (XIX) is formed at the isoelectric pH using an acid, hi one subclass of this class, the acid is selected from sulfuric acid or hydrochloric acid. In a subclass of this subclass, the acid is sulfuric acid. In another subclass of this class, the isoelectric pH is about 6 and a stoichiometric amount of acid is added.
  • the zwitterion of the pyrrolidine acid of formula (XLX) is recrystallized from a solvent selected from the group consisting of ethanol, isopropyl alcohol, methyl tert-butyl ether or a mixture thereof, h a subclass ofthis class, the solvent is a mixture of isopropyl alcohol and methyl tert-butyl ether. In a subclass ofthis subclass, the solvent is 1:3 isopropyl alcoho methyl tert-butyl ether.
  • the present invention also provides a process for the preparation of compounds of structural formula (XLX):
  • Rl is selected from the group consisting of
  • each R3 is independently selected from the group consisting of
  • OCH2CF3 in which heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, oxo, C ⁇ -4 alkyl, trifluoromethyl, and Ci-4 alkoxy; and wherein any methylene (CH2) carbon atom in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cl-4 alkyl; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
  • each R is independently selected from the group consisting of (1) hydrogen
  • alkyl, phenyl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with one to three groups independently selected from halogen, Cl-4 alkyl, hydroxy, and Ci-4 alkoxy; or two R4 groups together with the atom to which they are attached form a 4- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and NC ⁇ _4 alkyl; and n is 0, 1, 2, 3 or 4;
  • XVfll is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH.
  • the base is NaOH.
  • the base is aqueous NaOH.
  • the pyrrolidine compound of formula (XVITf) is hydrolyzed in a solvent selected from the group consisting of methanol, ethanol, and isopropanol.
  • the solvent is ethanol.
  • the compound of formula I is compound 1-9
  • the zwitterion is formed by the addition of sulfuric acid or hydrochloric acid
  • the zwitterion is formed by the addition of sulfuric acid.
  • the compound of formula I is compound 2
  • the zwitterion is formed by the addition of sulfuric acid or hydrochloric acid. In another class ofthis embodiment, the zwitterion is formed by the addition of sulfuric acid.
  • the compound of formula I is compound 3
  • the zwitterion is formed by the addition of sulfuric acid or hydrochloric acid. In another class of this embodiment, the zwitterion is formed by the addition of sulfuric acid.
  • alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration.
  • exemplary of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, and the like.
  • halogen is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.
  • aryl includes phenyl and naphthyl.
  • heteroaryl includes mono- and bicyclic aromatic rings containing from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur.
  • "5- or 6-Membered heteroaryl” represents a monocyclic heteroaromatic ring.
  • heteroaryls useful in this invention include wherein heteroaryl is selected from the group consisting of pyridinyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzofuryl, benzothienyl, indolyl, benzthiazolyl, and benzoxazolyl, and the like.
  • Bicyclic heteroaromatic rings include, but are not limited to, benzothiadiazole, indole, benzothiophene, benzofuran, benzimidazole, benzisoxazole, benzothiazole, quinoline, benzotriazole, benzoxazole, isoquinoline, purine, furopyridine and thienopyridine.
  • heteroaryl is selected from the group consisting of pyridinyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, triazolyl, triazinyl, tetrazolyl, thiadiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxathiazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzofuryl, benzothienyl, indolyl, benzthiazolyl, and benzoxazolyl.
  • cycloalkyl is intended to include non-aromatic rings containing only carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • heterocycloalkyl is intended to include non-aromatic heterocycles containing one to four heteroatoms selected from nitrogen, oxygen and sulfur.
  • examples of a 5 or 6-membered heterocycloalkyl include piperidine, morpholine, thiamorpholine, pyrrolidine, imidazolidine, tetrahydrofuran, piperazine, and the like. Certain of the above defined terms may occur more than once in the above formula and upon such occurrence each term shall be defined independently of the other; thus for example, NR 4 R 4 may represent NH2, NHCH3, N(CH 3 )CH2CH 3 , and the like.
  • the R-enantiomer of alcohol 1-2 may be prepared by treating 14. with (-) DIP chloride, or by treating 14 with a borane reducing agent and a catalyst, such as (R)-CBS or (R)-2-methyl CBS oxazaborolidine under similar reaction conditions.
  • the 3R, 4S diastereomer of 14 may be made in a similar fashion.
  • the reduction of acetophenone 1 may also be affected by treatment with sodium borohydride and trimethylsilyl chloride catalyzed by (S)- , ⁇ -diphenyl pyrrolidine methanol, or by treatment of acetophenone 14 via asymmetric transfer hydrogenation using chiral rhodium complex catalysis.
  • amino nitrile 1 ⁇ 5 Treatment of amino alcohol L4 with acrylonitrile and heating to reflux, followed by the addition of ethanol, formamide, or a mixture thereof, in the later stages of the reaction, affords the amino nitrile 1 ⁇ 5.
  • the amino nitrile X5 may be further purified by recrystallizing from heptane or hexane.
  • the pyrrolidine nitrile 1 7 was formed by the conversion of the alcohol of nitrile L5 into a leaving group by treatment with an alcohol activating reagent, such as CTPO(OEf)2, to form intermediate
  • intermediate L6 in situ.
  • a base such as lithium hexamethyldisilazide, sodium hexamethyldisilazide or potassium hexamethyldisilazide
  • R6 is Ci-4alkyl or phenyl.
  • Acid J 9 is formed from nitrile 1 7 via the amide intermediate J 8.
  • the pH at the isoelectric point is about pH 6.
  • the zwitterion of 1 ⁇ 9 may be recrystallized from ethanol to give the trans pyrrolidine acid zwitterion of 1-9.
  • the zwitterion of 1 ⁇ 9 may also be recrystallized as an HCl salt from acetonitrile.
  • (S)-Me CBS and (S)-2-methyl-CBS-OAB are (S)-2-methyl CBS oxazaborolidine;
  • BOC is tert-butyl carbamate;
  • DEAN diethyl aniline;
  • DMF is NN-dimethyl formamide;
  • EtOAc is ethyl acetate;
  • EtOH is ethanol;
  • g grams; h or hr is hours;
  • H2 is hydrogen;
  • HCl hydrochloric acid
  • HPLC high pressure liquid chromatography;
  • mmHg millimeters of mercury;
  • IPA is isopropyl alcohol;
  • kg is kilograms;
  • L is liters;
  • LiHMDS is lithium hexamethyl disilazide;
  • M is molar;
  • mL is milliliters;
  • MeOH is methanol, min is minutes, mol is moles;
  • Ms is methanesulfonyl;
  • Example 1 is provided to illustrate the invention and is not to be construed as limiting the scope of the invention in any manner.
  • a representative experimental procedure utilizing the novel process is detailed below.
  • the following Example is directed to the preparation of compound 1-9, but doing so is not intended to limit the present invention to a process for making that specific compound.
  • Step B Preparation of Compound 1-4
  • NaOH can be added. After 12-20 hours of refluxing, the mixture was concentrated in vacuo to 1/3 volume, then water (5 L) and MTBE (20 L) were added. The resulting layers were separated, and the aqueous phase was re-extracted with MTBE (2 x 2 L). The combined extracts were washed with saturated aqueous NaCI (1 L), then concentrated in vacuo. Heptane (40 L) was added and the concentration was continued to bring the volume to 20 L. The resulting mixture was then heated to -90 °C to dissolve all solids, and allowed to cool to 22 °C to crystallize over 4 hours. The mixture was then cooled to 0 °C, stirred 12-15 hr, and filtered.
  • a mixture of aminoethanol X4 from Step B (5.205 kg, 22.68 mol) and acrylonitrile (26.9 L, 408 mol) was heated at reflux (-77 °C) under a nitrogen atmosphere. After heating for 20 hours (with -90% conversion), one equivalent each of ethanol (1.32 L, 22.68 mol) and formamide (0.9 L, 22.68 mol) was added, and heating was continued for 12 hours. After cooling to 22 °C, the solution was concentrated by distillation (80-90 torr at 20-22 °C pot temperature) to 12 L volume. The resulting residue was diluted with isopropyl acetate (22 L) and re-concentrated (55-75 torr and 22-27 °C pot temperature).
  • the reaction mixture was quenched with water (50.6 L) at ⁇ 15 °C and extracted with n-heptane (40.5 L) at 20 °C.
  • the organic layer was washed with 10% aqueous NaCI solution (52 L).
  • the organic layer was carefully extracted with 3 N HCl solution (40.6 L, 121.8 mol) with cooling to keep the temperature ⁇ 35 °C.
  • the aqueous layer (58 L) was adjusted to pH 11-12 with 50% aq NaOH (6.13 L, 116.1 mol) and extracted with n-heptane (54 L). The layers were separated.
  • Cis- Pyrrolidine Nitrile-HCl Salt lH-NMR (d4-CH 3 OH, 400.25 MHz) ⁇ 7.57 (m, IH), 7.16-7.03 (om, 2H), 4.82 (s, OH), 4.20-4.08 (m, 2H),
  • the resulting slurry was heated to reflux (-80 °C) for 2 hours (which only partly dissolves product). The mixture was then allowed to cool. After cooling to 16 °C, MTBE (30.4 L, 3 volumes relative to IPA) was added to the mixture over 5 hours to give a 1:3 ratio of IPA:MTBE. After stirring at 16-17 °C for 3 days, the slurry was filtered, and the solids were washed with 12 L 1:3 IPA:MTBE. The solids were dried in vacuo (150 torr) at 50 °C, with a nitrogen sweep through the batch, for 3 days. Zwitterion IS was isolated as a white crystalline solid.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

A novel process is provided for the preparation of pyrrolidine carboxylic acids, and the useful intermediates obtained therein. These compounds are intermediates for the synthesis of melanocortin-4 receptor (MC-4R), which are useful for the treatment of disorders such as obesity, diabetes, male sexual dysfunction, and female sexual dysfunction.

Description

TITLE OF THE INVENTION
PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PYRROLIDINE CARBOXYLIC
ACIDS
BACKGROUND OF THE INVENTION
The present invention provides a process for the preparation of pyrrolidine carboxylic acids of general formula (I).
Figure imgf000002_0001
(I)
The present invention also provides intermediates useful in the disclosed process. The compounds of formula (I) are intermediates useful for the preparation of the pyrrolidine compounds of the general formula (II), wherein R2 is phenyl, unsubstituted or substituted with one to three R3 groups, r is 1 and s is 1.
Figure imgf000002_0002
(II)
The compounds of formula (II), along with their use as melanocortin receptor agonists were disclosed in WO 02/068387 (published on September 6, 2002), and WO 02/068388 (published on September 6, 2002). The compounds of formula (II) are also useful as agents for the treatment, control or prevention of diseases, disorders or conditions responsive to the activation of one or more of the melanocortin receptors including, but are not limited to, MC-1, MC-2, MC-3, MC-4, or MC-5. Such diseases, disorders or conditions include, but are not limited to, obesity, diabetes mellitus, hypertension, hyperlipidemia, osteoarthiitis, cancer, gall bladder disease, sleep apnea, depression, anxiety, compulsion, neuroses, insomnia/sleep disorder, substance abuse, pain, male and female sexual dysfunction, fever, inflammation, immune modulation, rheumatoid arthritis, skin tanning, acne and other skin disorders, neuroprotective and cognitive and memory enhancement including the treatment of Alzheimer' s disease. Some compounds encompassed by formula (II) show highly selective affinity for the melanocortin-4 receptor (MC-4R) relative to MC-IR, MC-2R, MC-3R, and MC-5R, which makes them especially useful in the prevention and treatment of obesity, as well as male and/or female sexual dysfunction, including erectile dysfunction. WO 02/068387 and WO 02/068388 describe processes for preparing the compounds of formula (II). However, the pyrrolidine acid was prepared in racemic forms and required a chiral HPLC chromatography. This resulted in the loss of all of the material prepared as the wrong enantiomer.
The present invention is directed to an efficient chiral synthesis that produces a pyrrolidine acid of structural formula (I) in a higher yield and utilizes less expensive chemical reagents. The synthetic sequence comprises 5 steps with an overall yield of about 71% and a chiral purity of >99.9 % ee of the pyrrolidine acid without the use of chromatography.
The synthesis of phenyl- and benzyl-substituted racemic pyrrolidines by intramolecular C-alkylation is described in Achini, R., Helvetica Chimica Acta, 64, 2203-2218 (1981). The asymmetric reduction of aryl chloromethyl-ketones is described in using (S)-MeCBS is described in Burkhardt, E.R. Tetr. Lett. 38, 1523-1526 (1997). The asymmetric transfer hydrogenation of ring-substituted 2-chloroacetophenone is reported by Noyori, et al., Org. Lett, 4, 4373 (2002). The reduction of 2-chloro-2',4'-difluoroacetophenone with NaBH-i/MesSiCl catalyzed by
(S)- ,α-diphenylpyrrolidinemethanol to give chlorohydrins is described in Jiang et al., Tetr. Lett., 41, 10281-10283 (2000). The rate acceleration of the Michael addition of tertiary amines to acrylonitrile using a polar solvent is disclosed in Aggarwal, V. et al., J. Org. Chem. 67, 510-514 (2002).
SUMMARY OF THE INVENTION
This invention is concerned with a process for preparing compounds of structural formula (I) and certain useful intermediates obtained during that process.
Figure imgf000003_0001
(I)
The novel process and novel intermediates can be exemplified in Scheme A, which shows the preparation of pyrrolidine acid (I).
The process involves the chiral reduction of the halogenated ketone (IV) to form a halogenated alcohol (V). The halogenated alcohol (V) is then converted to the amino alcohol (VII), via the epoxide intermediate (VI), by treatment with a base and subsequent treatment with a primary amine. The conjugate addition of the resulting amino alcohol (VII) to an α,β unsaturated nitrile or ester (Y= -CN or -CO2R5, and R5 is CI_4 alkyl) affords the tertiary amine (VIII). The alcohol of compound (VIII) is then converted to a leaving group (shown as -OZ in intermediate LX) by treatment with an alcohol activating reagent, such as C1P0(0R6)2, C1P0(N(R6)2)2, MSCI, Ms2θ, TsCl or Ts2θ. The resulting intermediate
(LX) is then treated with a base to facilitate the intramolecular cyclization to give a cis/trans mixture of pyrrolidine (X). The Y group of pyrrolidine (X) is then hydrolyzed /epimerized give the trans pyrrolidine acid (I).
Scheme A
Figure imgf000004_0001
Y
OH
H ( (XI) HO
R2 ^R M.
R2 ~R1
(VII) (Vlll)
Figure imgf000004_0002
Figure imgf000004_0003
(I)
X is Br or Cl; Y is -CN or -C02R5, R5 is ClΛ alkyl; V is an alkaline metal, such as Li, Na, or K; HMDS is hexamethyldisilazane; Z is -PO(OR6)2, -PO(N(R6)2)2, Ms, or Ts; R is Cj. alkyl or phenyl; R is H or C1-4 alkyl; and R and R are as defined supra.
Also provided are intermediate compounds which are useful for the preparation of compounds of structural formula (I).
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a process for the preparation of compounds of structural formula (I):
Figure imgf000005_0001
(D
wherein
Rl is selected from the group consisting of (1) hydrogen,
(2) amidino,
(3) Ci-4 alkyliminoyl,
(4) Ci-io alkyl,
(5) -(CH2)n-C3-7 cycloalkyl, (6) -(CH2)n-phenyl,
(7) -(CH2)n-naphthyl, and
(8) -(CH2)n-heteroaryl, in which phenyl, naphthyl, and heteroaryl are unsubstituted or substituted with one to three groups independently selected fromR3; and alkyl, cycloalkyl, and (CH2)n are unsubstituted or substituted with one to three groups independently selected from R3 and oxo;
R2 is selected from the group consisting of
(1) Ci_4 alkyl,
(2) -(CH2)n-cycloalkyl, (3) -(CH2)n-heterocycloalkyl,
(4) -(CH2)n-phenyl,
(5) -(CH2)n-naphthyl, and
(6) -(CH2)n-heteroaryl wherein heteroaryl is selected from the group consisting of (1) pyridinyl, (2) furyl,
(3) thienyl,
(4) pyrrolyl,
(5) oxazolyl,
(6) thiazolyl, (7) imidazolyl,
(8) pyrazolyl, (9) isoxazolyl,
(10) isothiazolyl,
(11) pyrimidinyl,
(12) pyrazinyl,
(13) pyridazinyl,
(14) quinolyl,
(15) isoquinolyl,
(16) benzimidazolyl,
(17) benzofuryl,
(18) benzothienyl,
(19) indolyl,
(20) benzthiazolyl, and
(21) benzoxazolyl; in which alkyl, phenyl, naphthyl, heteroaryl, and (CH2)n are unsubstituted or substituted with one to tliree groups independently selected fromR3;
each R3 is independently selected from the group consisting of
(1) -6 alkyl,
(2) -(CH2)n-phenyl,
(3) -(CH2)n-naphthyl,
(4) -(CH2)n-heteroaryl,
(5) -(CH2)n-heterocycloalkyl,
(6) -(CH2)nC3-7 cycloalkyl,
(7) halogen,
(8) OR4,
Figure imgf000006_0001
(10) N02,
Figure imgf000006_0002
(12) -(CH2)nS02N(R4)2,
(13) -(CH2)nS(0)pR4,
(14) CF3,
(15) CH2CF3>
(16) OCF3, and
(17) OCH2CF3; in which heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, oxo, Cι_4 alkyl, trifluoromethyl, and Cι_4 alkoxy; and wherein any methylene (CH2) carbon atom in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cl .4 alkyl; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
each R is independently selected from the group consisting of
(1) hydrogen,
(2) C1-6 alkyl,
(3) -(CH2)n-phenyl, (4) -(CH2)n-heteroaryl,
(5) -(CH2)n-naphthyl,
(6) -(CH2)n-heterocycloalkyl,
(7) -(CH2)nO3-7 cycloalkyl, and
(8) -(CH2)nC3-7 bicycloalkyl; wherein alkyl, phenyl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with one to three groups independently selected from halogen, Ci-4 alkyl, hydroxy, and C1-4 alkoxy; or two R4 groups together with the atom to which they are attached form a 4- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and NCχ.4 alkyl; and n is 0, 1, 2, 3 or 4;
comprising the steps of:
(a) preparing an alcohol of structural formula (V)
OH
,X
R2'
(V)
wherein X is bromide or chloride, and R2 is as defined above, by treating a ketone of structural formula (TV),
O
R2
(IV)
wherein X is bromide or chloride, and R2 is as defined above, with a reducing agent, and isolating the resulting product; (b) forming an amino alcohol of structural formula (VD)
QH H
(VII)
wherein Rl and R2 are as defined above, by treating an alcohol of structural formula (V), wherein X is chloride or bromide and R2 is as defined above,
OH ->J^ X*-
(V) with an amine of general formula RINH2, wherem Rl is as defined above, and a base in a solvent, and isolating the resulting product;
(c) forming a compound of structural formula (VUI)
Y OH
(Vlll)
wherein Y is -CN or -Cθ2R^ and R5 is Cι_4 alkyl, and wherem Rl and R2 are as defined above, by treating the amino alcohol of structural formula (VII)
9H H R2^ 1
(VII)
with a compound of general formula (XI)
(
(XI),
wherein Y is -CN or -Cθ2R^ , and R5 is Ci-4 alkyl, and isolating the resulting product; (d) forming a pyrrolidine compound of structural formula (X)
Figure imgf000009_0001
(X)
wherein Rl and R2 are as defined above, by treating the compound of structural formula (VIII), wherein Y, Rl and R2 are as defined above,
Figure imgf000009_0002
(Vlll)
with an alcohol activating reagent, followed by a base;
(e) forming a trans-pyrrolidine acid of structural formula (I)
Figure imgf000009_0003
(I)
wherein Rl and R2 are as defined above, by hydrolyzing the pyrrolidine compound of structural formula (X), wherein Y, Rl and R2 are as defined above,
Figure imgf000009_0004
(X)
with an aqueous base in a solvent; and
(f) isolating the resulting product.
In one embodiment of the present invention, R2 is phenyl or thienyl optionally substituted with one to three groups independently selected from R3. In a class of this embodiment, R2 is phenyl optionally substituted with one to three groups independently selected fromR3. Li a subclass of this class, R2 is selected from the group of phenyl; ortho, p ra-difluorophenyl; and /rørø-methoxyphenyl. In a subclass of this subclass, R is ortho, pora-difluorophenyl.
In another embodiment, R3 is selected from the group consisting of halogen, -CF3, and OR4. In a class of this embodiment of the present invention, R3 is selected from the group consisting of fluoride, bromide, chloride, -CF , and -OCι_6 alkyl. In a subclass of this class, R3 is selected from fluoride, bromide, -CF , and -OCH3.
In another embodiment, n is 0, 1 or 2. In a class of this embodiment n is 0 or 1. In a subclass of this embodiment, n is 0. In another embodiment of the present invention, the reducing agent used to treat the compound of formula (IV) of step (a) is (+)-DIP chloride.
In another embodiment of the present invention, the compound of formula (IV) of step (a) is treated with a reducing agent in the presence of a catalyst. In a class of this embodiment the reducing agent is selected from the group consisting of borane-N,N-diethyl aniline, borane-THF, and borane-dimethylsulfide. In a subclass of this class, the reducing agent is borane-N,N-diethyl aniline. In another class of this embodiment, the catalyst is selected from the group consisting of (S)-CBS and (S)-2-methyl CBS oxazaborolidine. In a subclass of this class, the catalyst is (S)-2-methyl CBS oxazaborolidine. h another embodiment of the present invention, alcohol of formula (V) is treated with an amine of general formula R NH2, wherein Rl is selected from the group consisting of hydrogen,
-(CH2)nphenyl, or Cl-6alkyl. In a class of this embodiment, Rl is tert-butyl or -CH2-phenyl. In a subclass of this class, Rl is tert-butyl.
In another embodiment of the present invention, the alcohol of formula (V) is treated with a base selected from the group consisting of NaOH, LiOH, KOH. In a class of this embodiment, the base is NaOH.
In another embodiment of the present mvention, the alcohol of formula (V) is treated in a solvent selected from methanol or ethanol. In a class of this embodiment, the solvent is methanol. In a subclass of this class, the solvent is refmxing methanol.
In another embodiment of the present invention, the amino alcohol of structural formula (VII) is isolated by recrystallization from heptane or hexane. In a class of this embodiment, the solvent is heptane.
In another embodiment of the present invention, the compound of formula (XI) is the compound wherein Y is CN. In another embodiment of the present invention, the compound of formula (XI) is the compound wherein Y is -Cθ2R^, wherein 5 is C1.4 alkyl. In a class of this embodiment Y is -CO2CH3, -Cθ2CH2CH3, or
-CO2CH2CH2CH2CH3. hi a subclass of this class, Y is -CO2CH2CH3, or -Cθ2CH2CH2CH2CH3.
In another embodiment of the present invention, the compound of formula (VIE) is formed by heating the mixture to reflux.
In another embodiment of the present invention, the compound of formula (VHl) is formed by adding ethanol, formamide or a mixture thereof. In a class of this embodiment, the compound of formula (VIU) is formed by adding a 1: 1 mixture of ethanol: formamide.
In another embodiment of the present invention, the compound of formula (VD3) is isolated by recrystallizing from heptane or hexane.
In another embodiment of the present invention, the compound of formula (VIE) is treated with an alcohol activating reagent selected from the group consisting of C1P0(0R6)2, C1P0(N(R6)2)2, MsCl, Ms2θ, TsCl, and Ts2θ, wherein R6 is C1.4 alkyl or phenyl. In a class of this embodiment, the alcohol activating reagent is chlorodiethyl phosphate.
In another embodiment of the present invention, the compound of formula (VHl) is treated with a base selected from the group consisting of lithium hexamethyldisilazide, sodium hexamethyl disilazide, and potassium hexamethyldisilazide. In a class of this embodiment, the base is lithium hexamethyl disilazide.
In another embodiment of the present invention, the compound of formula (VIU) is treated at a temperature of about -30 to about + 10 C. In a class of this embodiment, the temperature is about -15 C.
In another embodiment of the present invention, the pyrrolidine compound of formula (X) is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH. In one class of this embodiment, the base is NaOH. In a subclass of this class, the base is aqueous NaOH.
In another embodiment of the present invention, the pyrrolidine compound of formula (X) is hydrolyzed in a solvent selected from the group consisting of methanol, ethanol, and isopropanol. h a class of this embodiment, the solvent is ethanol. In another embodiment, the product of step (f) is isolated by forming a zwitterion of the trans pyrrolidine acid of structural formula (I)
Figure imgf000011_0001
(I) wherein Rl and R2 are as defined above, recrystallizing the zwitterion from a solvent; and isolating the resulting product.
In a class ofthis embodiment the zwitterion of the pyrrolidine acid of formula (I) is formed at the isoelectric pH using an acid or a base, h one subclass of this class, the acid is selected from sulfuric acid or hydrochloric acid. In a subclass ofthis subclass, the acid is sulfuric acid. In another subclass ofthis class, the isoelectric pH is about 6 and a stoichiometric amount of acid is added.
In another class ofthis embodiment, the zwitterion of the pyrrolidine acid of formula (I) is recrystallized from a solvent selected from the group consisting of ethanol, isopropyl alcohol, methyl tert-butyl ether or a mixture thereof. In a subclass ofthis class, the solvent is a mixture of isopropyl alcohol and methyl tert-butyl ether. In a subclass of this subclass, the solvent is 1:3 isopropyl alcohoLmethyl tert-butyl ether.
The present invention also provides a process for the preparation of compounds of structural formula (I):
Figure imgf000012_0001
(D
wherein
Rl is selected from the group consisting of
(1) hydrogen,
(2) amidino, (3) Ci-4 alkyliminoyl,
(4) Ci-io alkyl,
(5) -(CH2)n-C3_7 cycloalkyl,
(6) -(CH2)n-phenyl,
(7) -(CH2)n-naphthyl, and (8) -(CH2)n-heteroaryl, in which phenyl, naphthyl, and heteroaryl are unsubstituted or substituted with one to three groups independently selected from R3; and alkyl, cycloalkyl, and (CH2)n are unsubstituted or substituted with one to three groups independently selected from R and oxo;
R is selected from the group consisting of (1) Ci-4 alkyl, (2) -(CH2)n-cycloalkyl,
(3) -(CH2)n-heterocycloalkyl,
(4) -(CH2)n-phenyl,
(5) -(CH2)n-naphthyl, and
(6) -(CH2)n-heteroaryl wherein heteroaryl is selected from the group consisting of
(1) pyridinyl,
(2) furyl,
(3) thienyl,
(4) pyrrolyl,
(5) oxazolyl,
(6) thiazolyl,
(7) imidazolyl,
(8) pyrazolyl,
(9) isoxazolyl,
(10) isothiazolyl,
(11) pyrimidinyl,
(12) pyrazinyl,
(13) pyridazinyl,
(14) quinolyl,
(15) isoquinolyl,
(16) benzimidazolyl,
(17) benzofuryl,
(18) benzothienyl,
(19) indolyl,
(20) benzthiazolyl, and
(21) benzoxazolyl; in which alkyl, phenyl, , naphthyl, heteroaryl, and (CH2)n are unsubstituted or substituted with one to three groups independently selected from R3;
each R3 is independently selected from the group consisting of
(1) Cι_6 alkyl,
(2) -(CH2)n-phenyl,
(3) -(CH2)n-naphthyl,
(4) -(CH2)n-heteroaryl, (5) -(CH2)n-heterocycloalkyl, (6) -(CH2)nC3-7 cycloalkyl,
(7) halogen,
(8) OR4,
(9) -(CH2)nN(R4)2, (10) Nθ2,
Figure imgf000014_0001
(12) -(CH2)nS02N(R4)2,
(13) -(CH2)nS(0)pR4,
(14) CF3, (15) CH2CF3,
(16) OCF3, and
(17) OCH2CF3; in which heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, oxo, Ci-4 alkyl, trifluoromethyl, and Ci-4 alkoxy; and wherein any methylene (CH2) carbon atom in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cχ_4 alkyl; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
each R4 is independently selected from the group consisting of
(1) hydrogen,
(2) C1 -6 alkyl,
(3) -(CH2)n-phenyl,
(4) -(CH2)n-heteroaryl, (5) -(CH2)n-naphthyl,
(6) -(CH2)n-heterocycloalkyl,
(7) -(CH2)nC3-7 cycloalkyl, and
(8) -(CH2)nC3-7 bicycloalkyl; wherein alkyl, phenyl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with one to three groups independently selected from halogen, Ci-4 alkyl, hydroxy, and Ci-4 alkoxy; or two R4 groups together with the atom to which they are attached form a 4- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and NCi-4 alkyl; and n is 0, 1, 2, 3 or 4;
comprising the steps of: (a) hydrolyzing a pyrrolidine compound of structural formula (X), wherein Y, Rl and R2 are as defined above,
Figure imgf000015_0001
(X)
with an aqueous base in a solvent; and
(b) isolating the resulting product.
In another embodiment of the present invention, the pyrrolidine compound of formula (X) is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH. In one class of this embodiment, the base is NaOH. In a subclass of this class, the base is aqueous NaOH. In another embodiment of the present invention, the pyrrolidine compound of formula (X) is hydrolyzed in a solvent selected from the group consisting of methanol, ethanol, and isopropanol. In a class of this embodiment, the solvent is ethanol.
The present invention also provides a process for the preparation of compounds of structural formula (XLX):
Figure imgf000015_0002
(XIX)
wherein
Rl is selected from the group consisting of (1) hydrogen, (2) amidino,
(3) Ci-4 alkyliminoyl,
(4) Cι_ιo alkyl,
(5) -(CH2)n-C3„7 cycloalkyl,
(6) -(CH2)n-phenyl, (7) -(CH2)n-naphthyl, and
(8) -(CH2)n-heteroaryl, in which phenyl, naphthyl, and heteroaryl are unsubstituted or substituted with one to three groups independently selected fromR3; and alkyl, cycloalkyl, and (CH2)n are unsubstituted or substituted with one to three groups independently selected from R3 and oxo;
each R3 is independently selected from the group consisting of
(1) Cι_6 alkyl,
(2) -(CH2)n-phenyl,
(3) -(CH2)n-naphthyl,
(4) -(CH2)n-heteroaryl, (5) -(CH2)n-heterocycloalkyl,
(6) -(CH2)nC -7 cycloalkyl,
(7) halogen,
(8) OR4,
(9) -(CH2)nN(R4)2, (10) N0 ,
Figure imgf000016_0001
(12) -(CH2)nS02N(R4)2,
(13) -(CH2)nS(0)pR4
(14) CF3, (15) CH2CF ,
(16) OCF3, and
(17) OCH2CF3; in which heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, oxo, Cι_4 alkyl, trifluoromethyl, and Ci-4 alkoxy; and wherein any methylene (CH2) carbon atom in R is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cι_4 alkyl; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
each R4 is independently selected from the group consisting of
(1) hydrogen,
(2) -6 alkyl,
(3) -(CH2)n-phenyl,
(4) -(CH2)n-heteroaryl,
(5) -(CH2)n-naphthyl,
(6) -(CH2)n-heterocycloalkyl, (7) -(CH2)nC3-7 cycloalkyl, and
(8) -(CH2)nC3-7 bicycloalkyl; wherein alkyl, phenyl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with one to three groups independently selected from halogen, Ci-4 alkyl, hydroxy, and Ci-4 alkoxy; or two R4 groups together with the atom to which they are attached form a 4 - to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and NCi .4 alkyl; and n is 0, 1, 2, 3, or 4;
comprising the steps of: (a) preparing an alcohol of structural formula (XTTT)
Figure imgf000017_0001
(XIII)
wherein X is bromide or chloride, and R3 is as defined above, by treating a ketone of structural formula (XII),
Figure imgf000017_0002
wherein X is bromide or chloride, and R is as defined above, with a reducing agent, and isolating the resulting product;
(b) forming an amino alcohol of structural formula (XV)
Figure imgf000017_0003
wherein Rl and R3 are as defined above, by treating an alcohol of structural fprmula (XIII)
Figure imgf000018_0001
(XIII)
wherein X is chloride or bromide and R3 are as defined above, with an amine of general formula RINH2, wherein R is as defined above, and a base in a solvent, and isolating the resulting product;
(c) forming a compound of structural formula (XVI), wherein Y is -CN or -Cθ2R^ and R is
Ci -4 alkyl, and R and R3 are as defined above,
Figure imgf000018_0002
by treating the amino alcohol of structural formula (XV) wherein Rl and R3 are as defined above,
Figure imgf000018_0003
with a compound of general formula (XI)
(XI)
wherein Y is -CN or -Cθ2R^ , and R5 is Ci_4 alkyl, and isolating the resulting product;
(d) forming a pyrrolidine compound of structural formula (XVIII) wherein Y, Rl and R3 are as defined above,
Figure imgf000019_0001
by treating the compound of structural formula (XVI), wherein Y, Rl and R are as defined above,
Figure imgf000019_0002
with an alcohol activating reagent, followed by a base;
(e) forming a pyrrolidine acid of structural formula (XLX), wherein Rl and R3 are as defined above,
Figure imgf000019_0003
(XIX)
by hydrolyzing the pyrrolidine compound of structural formula (XVIII), wherein Y, Rl and R are as defined above,
Figure imgf000019_0004
with an aqueous base in a solvent; and
(f) isolating the resulting product.
In one embodiment, 3 is selected from the group consisting of halogen, -CF3, and OR4.
In a class of this embodiment of the present invention, R3 is selected from the group consisting of fluoride, bromide, chloride, -CF3, and -OCχ-6 alkyl. In a subclass ofthis class, R3 is selected from fluoride, bromide, CF3, and -OCH3. h another embodiment of the present invention, the reducing agent used to treat the compound of formula (XII) of step (a) is (+)-DIP chloride. In another embodiment of the present invention, the compound of formula (XII) of step (a) is treated with a reducing agent in the presence of a catalyst. In a class of this embodiment the reducing agent is selected from the group consisting of borane-N,N-diethyl aniline, borane-THF, and borane-dimethylsulfide. hi a subclass ofthis class, the reducing agent is borane-N,N-diethyl aniline. In another class of this embodiment, the catalyst is selected from the group consisting of (S)-CBS and (S)-2-methyl CBS oxazaborolidine. In a subclass ofthis class, the catalyst is (S)-2-methyl CBS oxazaborolidine. i another embodiment of the present invention, alcohol of formula (Xlfl) is treated with an amine of general formula R H2, wherein Rl is selected from the group consisting of hydrogen, -(CH2)nPhenyl, or Ci-βalkyl. In a class ofthis embodiment, l is tert-butyl or -CH2-phenyl. In a subclass of this class, Rl is tert-butyl.
In another embodiment of the present invention, the alcohol of formula (Xfll) is treated with a base selected from the group consisting of NaOH, LiOH, KOH. In a class of this embodiment, the base is NaOH.
In another embodiment of the present invention, the alcohol of formula (XIII) is treated in a solvent selected from methanol or ethanol. In a class of this embodiment, the solvent is methanol. In a subclass of this class, the solvent is refluxing methanol.
In another embodiment of the present mvention, the amino alcohol of structural formula (XV) is isolated by recrystallization from heptane or hexane. In a class of this embodiment, the solvent is heptane. In another embodiment of the present invention, the compound of formula (XI) is the compound wherein Y is CN. hi another embodiment of the present invention, the compound of formula (XI) is the compound wherein Y is -Cθ2R^, wherein R^ is Ci-4 alkyl. In a class ofthis embodiment Y is -CO2CH3, -Cθ2CH2CH3, or -Cθ2CH2CH2CH2CH3. In a subclass of this class, Y is -Cθ2CH2CH3, or -Cθ2CH2CH2CH2CH .
In another embodiment of the present invention, the compound of structural formula (XVI) is formed by heating the mixture to reflux. In another embodiment of the present invention, the compound of structural formula (XVI) is formed by adding ethanol, formamide or a mixture thereof. In a class ofthis embodiment, the compound of structural formula (XVI) is formed by adding a 1:1 mixture of ethanol:formamide. i another embodiment of the present invention, the compound of structural formula (XVI) is isolated by recrystallizing from heptane or hexane.
In another embodiment of the present invention, the compound of structural formula (XVI) is treated with an alcohol activating reagent selected from the group consisting of C1P0(0R6)2, ClPO(N(R6)2)2, MsCl, Ms2θ, TsCl, and Ts2θ, wherein R6 is C1-4 alkyl or phenyl. In a class of this embodiment, the alcohol activating reagent is chlorodiethyl phosphate. In another embodiment of the present invention, the compound of structural formula (XVI) is treated with a base selected from the group consisting of lithium hexamethyldisilazide, sodium hexamethyl disilazide, and potassium hexamethyldisilazide. In a class of this embodiment, the base is lithium hexamethyl disilazide.
In another embodiment of the present invention, the compound of structural formula (XVT) is treated at a temperature of about -30 to about +10 C. In a class of this embodiment, the temperature is about -15 C. i another embodiment of the present invention, the pyrrolidine compound of formula (XViπ) is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH. In one class ofthis embodiment, the base is NaOH. hi a subclass ofthis class, the base is aqueous NaOH. another embodiment of the present invention, the pyrrolidine compound of formula
(XVIH) is hydrolyzed in a solvent selected from the group consisting of methanol, ethanol, and isopropanol. h a class of this embodiment, the solvent is ethanol.
In another embodiment, the product of step (f) is isolated by forming a zwitterion of the trans pyrrolidine acid of structural formula (XLX)
Figure imgf000021_0001
(XIX)
wherein l and R3 are as defined above; recrystallizing the zwitterion from a solvent; and isolating the resulting product.
In a class of this embodiment the zwitterion of the pyrrolidine acid of formula (XIX) is formed at the isoelectric pH using an acid, hi one subclass of this class, the acid is selected from sulfuric acid or hydrochloric acid. In a subclass of this subclass, the acid is sulfuric acid. In another subclass of this class, the isoelectric pH is about 6 and a stoichiometric amount of acid is added. In another class of this embodiment, the zwitterion of the pyrrolidine acid of formula (XLX) is recrystallized from a solvent selected from the group consisting of ethanol, isopropyl alcohol, methyl tert-butyl ether or a mixture thereof, h a subclass ofthis class, the solvent is a mixture of isopropyl alcohol and methyl tert-butyl ether. In a subclass ofthis subclass, the solvent is 1:3 isopropyl alcoho methyl tert-butyl ether.
The present invention also provides a process for the preparation of compounds of structural formula (XLX):
Figure imgf000022_0001
(XIX)
wherein
Rl is selected from the group consisting of
(1) hydrogen,
(2) amidino, (3) Ci-4 alkyliroinoyl,
(4) Ci-10 alkyl,
(5) -(CH2)n-C3-7 cycloalkyl,
(6) -(CH2)n-phenyl,
(7) -(CH2)n-naphthyl, and (8) -(CH2)n-heteroaryl, in which phenyl, naphthyl, and heteroaryl are unsubstituted or substituted with one to three groups independently selected from R3; and alkyl, cycloalkyl, and (CH2)n are unsubstituted or substituted with one to three groups independently selected from 3 and oxo;
each R3 is independently selected from the group consisting of
(1) Ci-6 alkyl,
(2) -(CH2)n-phenyl,
(3) -(CH2)n-naphthyl,
(4) -(CH2)n-heteroaryl, (5) -(CH2)n-heterocycloalkyl,
(6) -(CH2)nC3-7 cycloalkyl, (7) halogen,
(8) OR4
(9) -(CH2)nN(R4)2,
(10) N02, (11) -(CH2)nNR4S02R4,
(12) -(CH2)nS02N(R4)2,
(13) -(CH2)nS(0)pR4,
(14) CF3,
(15) CH2CF3, (16) OCF3, and
(17) OCH2CF3; in which heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, oxo, Cχ-4 alkyl, trifluoromethyl, and Ci-4 alkoxy; and wherein any methylene (CH2) carbon atom in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cl-4 alkyl; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
each R is independently selected from the group consisting of (1) hydrogen,
(2) C1 -6 alkyl,
(3) -(CH2)n-phenyl,
(4) -(CH2)n-heteroaryl,
(5) -(CH2)n-naphthyl, (6) -(CH2)n-heterocycloalkyl,
(7) -(CH2)nC3-7 cycloalkyl, and
(8) -(CH2)nC3-7 bicycloalkyl; wherein alkyl, phenyl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with one to three groups independently selected from halogen, Cl-4 alkyl, hydroxy, and Ci-4 alkoxy; or two R4 groups together with the atom to which they are attached form a 4- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and NCι_4 alkyl; and n is 0, 1, 2, 3 or 4;
comprising the steps of: (a) hydrolyzing a pyrrolidine compound of structural formula (XVBT), wherein Y, Rl and R are as defined above,
Figure imgf000024_0001
(XVIII)
with an aqueous base in a solvent; and
(b) isolating the resulting product. In another embodiment of the present invention, the pyrrolidine compound of formula
(XVfll) is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH. In one class ofthis embodiment, the base is NaOH. In a subclass ofthis class, the base is aqueous NaOH.
In another embodiment of the present invention, the pyrrolidine compound of formula (XVITf) is hydrolyzed in a solvent selected from the group consisting of methanol, ethanol, and isopropanol. In a class of this embodiment, the solvent is ethanol.
In a further embodiment ofthis invention, the compound of formula I is compound 1-9
Figure imgf000024_0002
1-8 ;
or a zwitterion or salt thereof. In a class of this embodiment, the zwitterion is formed by the addition of sulfuric acid or hydrochloric acid, hi another class ofthis embodiment, the zwitterion is formed by the addition of sulfuric acid.
In a further embodiment of his invention, the compound of formula I is compound 2
Figure imgf000024_0003
or a zwitterion or salt thereof. In a class ofthis embodiment, the zwitterion is formed by the addition of sulfuric acid or hydrochloric acid. In another class ofthis embodiment, the zwitterion is formed by the addition of sulfuric acid. hi a further embodiment of this invention, the compound of formula I is compound 3
Figure imgf000025_0001
or a zwitterion or salt thereof. In a class ofthis embodiment, the zwitterion is formed by the addition of sulfuric acid or hydrochloric acid. In another class of this embodiment, the zwitterion is formed by the addition of sulfuric acid.
Throughout the instant application, the following terms have the indicated meanings:
The alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration. Exemplary of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, and the like.
The term "halogen" is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.
The term "aryl" includes phenyl and naphthyl.
The term "heteroaryl" includes mono- and bicyclic aromatic rings containing from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur. "5- or 6-Membered heteroaryl" represents a monocyclic heteroaromatic ring. Examples of heteroaryls useful in this invention include wherein heteroaryl is selected from the group consisting of pyridinyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzofuryl, benzothienyl, indolyl, benzthiazolyl, and benzoxazolyl, and the like. Bicyclic heteroaromatic rings include, but are not limited to, benzothiadiazole, indole, benzothiophene, benzofuran, benzimidazole, benzisoxazole, benzothiazole, quinoline, benzotriazole, benzoxazole, isoquinoline, purine, furopyridine and thienopyridine. i one embodiment of the present invention, heteroaryl is selected from the group consisting of pyridinyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, triazolyl, triazinyl, tetrazolyl, thiadiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxathiazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzofuryl, benzothienyl, indolyl, benzthiazolyl, and benzoxazolyl.
The term "cycloalkyl" is intended to include non-aromatic rings containing only carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
The term "heterocycloalkyl" is intended to include non-aromatic heterocycles containing one to four heteroatoms selected from nitrogen, oxygen and sulfur. Examples of a 5 or 6-membered heterocycloalkyl include piperidine, morpholine, thiamorpholine, pyrrolidine, imidazolidine, tetrahydrofuran, piperazine, and the like. Certain of the above defined terms may occur more than once in the above formula and upon such occurrence each term shall be defined independently of the other; thus for example, NR4R4 may represent NH2, NHCH3, N(CH3)CH2CH3, and the like.
The process and intermediates of the present invention can be exemplified with the preparation of (3S,4R)-N-tert-Butyl~4(2,4-difluorophenyl)- pyrrolidine 3-carboxylic acid (1-9) as shown in Scheme 1.
Scheme 1
F
Figure imgf000026_0001
1-1 1-2
Figure imgf000026_0002
As shown in Scheme 1, the known (3S,4R)-N-tert-Butyl-4- (2,4-difluorophenyl)pyrrolidine 3-carboxylic acid (1-9) is prepared as follows.
The asymmetric reduction of 2-chloro-2' ,4'-difluoroacetophenone 14. with a reducing agent, such as (+) DIP chloride; or with a reducing agent such as borane-diethyl aniline, borane dimethyl-sulfide, or borane-THF in the presence of a catalyst, such as (S)-CBS, or (S)-2-methyl CBS oxazaborolidine. The reaction is run in a solvent such as diisopropyl ether, MTBE, toluene, or THF, at a temperature of about -20 to +60°C, and optimally at a temperature of about +30 to +50°C, to afford the (S)-alcohol !ι2. When (S)-2-methyl CBS oxazaborolidine and borane-diethyl aniline are used for the reduction, and the reduction is run at a temperature of about 40°C, then the use of 0.5 mole % of (S)-CBS catalyst results in the formation of 98.88 % ee of the S-enantiomer of alcohol 1X2. The R-enantiomer of alcohol 1-2 may be prepared by treating 14. with (-) DIP chloride, or by treating 14 with a borane reducing agent and a catalyst, such as (R)-CBS or (R)-2-methyl CBS oxazaborolidine under similar reaction conditions. By reducing 14 with the (-) DIP chloride, or with a borane reducing agent and (R)-CBS or (R)-2-methyl CBS oxazaborolidine, the 3R, 4S diastereomer of 14 may be made in a similar fashion. The reduction of acetophenone 1 may also be affected by treatment with sodium borohydride and trimethylsilyl chloride catalyzed by (S)- ,α-diphenyl pyrrolidine methanol, or by treatment of acetophenone 14 via asymmetric transfer hydrogenation using chiral rhodium complex catalysis.
Treatment of alcohol 1^2 with a base, such as sodium hydroxide, lithium hydroxide or potassium hydroxide, in a protic solvent, such as methanol or ethanol, and subsequently heating to reflux results in the formation of the epoxide intermediate Lθ in situ. Opening the epoxide ring with a primary amine, such as a C s alkyl amine, benzyl amine or substituted benzylamine, affords the amino alcohol 1-4.
Crystallization of L4 from heptane or hexanes gives amino alcohol L4 as >99.9% ee of the S-enantiomer.
When methanol and tez -butyl amine are used to prepare amino alcohol 1-4, the optimal ratio of methanol to tert-butyl amine is 1:5. The treatment of the epoxide intermediate with benzyl amine and the subsequent removal of the benzyl protecting group under standard conditions, such as hydrogenation, is useful to prepare compounds of formula I in which Rl is H.
Treatment of amino alcohol L4 with acrylonitrile and heating to reflux, followed by the addition of ethanol, formamide, or a mixture thereof, in the later stages of the reaction, affords the amino nitrile 1^5. The amino nitrile X5 may be further purified by recrystallizing from heptane or hexane. The pyrrolidine nitrile 1 7 was formed by the conversion of the alcohol of nitrile L5 into a leaving group by treatment with an alcohol activating reagent, such as CTPO(OEf)2, to form intermediate
1-6 in situ. Subsequent treatment of intermediate L6 with a base, such as lithium hexamethyldisilazide, sodium hexamethyldisilazide or potassium hexamethyldisilazide, at a temperature of about -30 to about +10°C yields a cis/trans mixture of the pyrrolidine nitrile L . Other alcohol activating reagents useful to convert the alcohol into a leaving group include, but are not limited to, ClPO(OR6)2, C1P0(Ν(R6)2)2, MsCl, Ms2θ, TsCl or Ts2θ, wherein R6 is Ci-4alkyl or phenyl. Acid J 9 is formed from nitrile 1 7 via the amide intermediate J 8. The kinetically controlled hydrolysis/epimerization of pyrrolidine nitrile j-7 with an aqueous base, such as sodium hydroxide, lithium hydroxide or potassium hydroxide, in a protic solvent, such as methanol, ethanol, or isopropanol, at reflux, and the subsequent adjustment of the pH to the isoelectric point of I . with an acid, such as sulfuric acid or HCl, affords the zwitterion of 1^9. The pH at the isoelectric point is about pH 6. The zwitterion of 1^9 may be recrystallized from ethanol to give the trans pyrrolidine acid zwitterion of 1-9. The zwitterion of 1^9 may also be recrystallized as an HCl salt from acetonitrile.
Abbreviations Used in the Description of the Preparation of the Compounds of the Present Invention: (S)-Me CBS and (S)-2-methyl-CBS-OAB are (S)-2-methyl CBS oxazaborolidine; BOC is tert-butyl carbamate; DEAN is diethyl aniline; DMF is NN-dimethyl formamide; EtOAc is ethyl acetate; EtOH is ethanol; g is grams; h or hr is hours; H2 is hydrogen; HCl is hydrochloric acid, HPLC is high pressure liquid chromatography; mmHg is millimeters of mercury; IPA is isopropyl alcohol; kg is kilograms; L is liters; LiHMDS is lithium hexamethyl disilazide; M is molar; mL is milliliters; MeOH is methanol, min is minutes, mol is moles; Ms is methanesulfonyl; MTBE is methyl t-butyl ether; Ν is normal; ΝMP is Ν-methyl pyrrolidinone; ΝaCl is sodium chloride; ΝMR is nuclear magnetic resonance; OAc is acetate; Ts is toluenesulfonyl; THF is tetrahydrofuran; and ClPO(OEf)2 is chloro diethyl phosphate.
The following Example is provided to illustrate the invention and is not to be construed as limiting the scope of the invention in any manner. A representative experimental procedure utilizing the novel process is detailed below. For purposes of illustration, the following Example is directed to the preparation of compound 1-9, but doing so is not intended to limit the present invention to a process for making that specific compound.
EXAMPLE 1
(3S.4R)-N-tert-Butyl-4(2.4-difluorophenyl)pyrrolidine 3-carboxylic acid (1-9) Step A: Preparation of Compound 1-2
Figure imgf000028_0001
1-1 1-2
A solution of (S)-2-methyl-CBS-OAB (128 mL of 1.0M solution in toluene, Aldrich), borane-NN-diethylaniline (25.7 mol, Gallery) in MTBE (10 L) was heated to 38-42 °C, followed by the addition of a solution of 2-chloro-2',4'-difluoro-acetophenone (4891 g, Apollo) in MTBE (14.7 L) over 10 hours. The resulting homogeneous solution was stirred at 40 °C for one hour, and then cooled to 18 °C and stirred overnight. Methanol (2.3 L) was added over 60 minutes, while maintaining the temperature at <20 °C with cooling. The resulting homogeneous solution was stirred for 30 minutes, then dilute with water (24 L) and 5 N aqueous HCl (10 L) was added over 30 minutes, while maintaining the temperature at 22-25 °C with cooling. After stirring 30 minutes, the layers were separated. The organic layer was washed with saturated aqueous NaCI, and then concentrated in vacuo to give chloro-alcohol X2. The chiral assay of the chloro-alcohol gave a 99.44:0.56 ratio of S:R enantiomers (98.88% ee). 1H-NMR (CDC13, 400.25 MHz) δ 7.51 (m, IH), 6.91 (m, IH), 6.80 (m, IH), 5.16 (dd, 7 = 8.2, 3.2 Hz, IH),
3.79 (dd, 7 = 11.2, 3.4 Hz, IH), 3.62 (dd, J = 11.2, 8.2 Hz, IH), 3.02 (s, IH).
13C NMR (CDC13, 100.65 MHz) δ 162.7 (dd, 7= 249.6, 12.0 Hz), 159.7 (dd, 7= 248.5, 11.7 Hz), 128.6 (dd,
7=9.7, 5.7 Hz), 123.0 (dd, 7=13.5, 3.8 Hz), 111.6 (dd, 7 = 21.2, 3.7 Hz), 103.8 (t, 7 = 25.4 Hz), 67.8 (d, 2.1
Hz), 49.4.
BP: 69-71 °C at l5 mmHg.
Step B: Preparation of Compound 1-4
Figure imgf000029_0001
The concentrated MTBE solution of l£2 from Step A (5040 g, 25.67 mol) was diluted with methanol (5 L), then tert-butylamine (25 L) was added. The mixture warmed upon mixing to 45 °C. The mixture was then cooled to 25 °C and solid NaOH pellets (1048 g) were added. No exotherm was observed, and the mixture was stirred and warmed to reflux. After 2 hours, if chloro-alcohol remains, additional
NaOH can be added. After 12-20 hours of refluxing, the mixture was concentrated in vacuo to 1/3 volume, then water (5 L) and MTBE (20 L) were added. The resulting layers were separated, and the aqueous phase was re-extracted with MTBE (2 x 2 L). The combined extracts were washed with saturated aqueous NaCI (1 L), then concentrated in vacuo. Heptane (40 L) was added and the concentration was continued to bring the volume to 20 L. The resulting mixture was then heated to -90 °C to dissolve all solids, and allowed to cool to 22 °C to crystallize over 4 hours. The mixture was then cooled to 0 °C, stirred 12-15 hr, and filtered. The filtrate was washed with cold heptane (2 x 5 L), then dried in vacuo at 35 °C to obtain the crystalline amino-alcohol L4. The chiral assay of L gave a >99.95 : 0.05 ratio of S:R enantiomers (>99.9% ee). 1H-NMR (CDCI3, 400.25 MHz) δ 7.52 (m, IH), 6.88 (m, IH), 6.76 (m, IH), 4.85 (dd, 7 = 8.6, 3.4, IH),
2.94 (m, IH), 2.52 (m, IH), 1.10 (s, 9H).
13C NMR (CDCI3, 100.65 MHz) δ 162.1 (dd, 7 = 247.4, 12.0), 159.7 (dd, 7 = 247.9, 12.0), 128.3 (dd, 7 =
13.6, 3.8), 111.1 (dd, 7 =20.9, 3.5), 103.4 (t, 7 = 32.0), 66.0, 50.4, 48.7, 29.1 (3C). MP (DSC): onset
115.35 °C, end 118.66 °C, peak 117.22 °C.
Anal. Calcd for C12H17F2NO: Calc, C, 62.87, H, 7.47, F, 16.57, N, 6.11. Found, C, 62.93, H, 7.67, F,
16.24, N, 6.13.
Step C: Preparation of Compound 1-5
Figure imgf000030_0001
1-4 1-5
A mixture of aminoethanol X4 from Step B (5.205 kg, 22.68 mol) and acrylonitrile (26.9 L, 408 mol) was heated at reflux (-77 °C) under a nitrogen atmosphere. After heating for 20 hours (with -90% conversion), one equivalent each of ethanol (1.32 L, 22.68 mol) and formamide (0.9 L, 22.68 mol) was added, and heating was continued for 12 hours. After cooling to 22 °C, the solution was concentrated by distillation (80-90 torr at 20-22 °C pot temperature) to 12 L volume. The resulting residue was diluted with isopropyl acetate (22 L) and re-concentrated (55-75 torr and 22-27 °C pot temperature). The dilution and re-concentration was repeated, and then the resulting residue was diluted with isopropyl acetate to a total volume of 34 L. Gummy polymer that was present was allowed to settle after stopping the stirrer, and the bulk of the supernatant was filtered (10-15 um porosity), followed by the rest of material. The filter cake was washed with isopropyl acetate and the filtrate was diluted with a total of 24 L of isopropyl acetate. The combined filtrate (-54 L) was washed with a solution made up of water (31.2 L), acetic acid (52 mL, 4 mol%), and saturated brine (3.1 L). This was followed by a 12% aqueous NaCI wash (2 x 34 L). The organic layer was concentrated (15-45 torr and 5-29 °C) to -15 L volume and flushed with 5 x 6 L portions of n-heptane, during which time product crystallized. The slurry was diluted with n-heptane to a volume of 23 L. The mixture was stirred at 0-5 °C for 3 days, then filtered and washed with cold (5 °C) π-heptane (14 L). The wet cake was dried in vacuo at 20 °C with a nitrogen sweep for 4 days to afford nitrile j^5 as a crystalline white solid. The chiral assay of crystalline nitrile L5 was >99.99 area % as the desired S-enant- iomers. lH-NMR (400.25 MHz, CDC13) δ 7.55 (m, IH), 6.90 (m, IH), 6.77 (m, IH), 4.84 (dd, 7 = 10.2, 3.1, IH),
3.66 (OH, IH), 3.00-2.83 (om, 3H), 2.62-2.47 (om, 2H), 2.45 (dd, 7= 13.9, 10.3, IH), 1.15 (s, 9H). 13C-NMR (100.65 MHz, CDC13) δ 162.1 (dd, 7 = 247.7, 11.9), 159.6 (dd, 7 = 247.5, 11.9), 128.0 (dd, 7 =
9.5, 6.5), 125.1 (dd, 13.7, 3.6), 118.6, 111.4 (dd, 7 = 20.9, 3.3), 103.4 (t, 7 = 25.6), 65.4, 57.9, 55.7, 47.3,
27.2 (3C), 20.2.
19F-NMR (376.61 MHz, CDCI3) δ -112.25 (d, 7 = 6.9), -116.27 (d, 6.8).
MP (DSC): onset 60.20 °C, end 64.15 °C, peak 62.61 °C.
Anal. Calcd for C15H20F2N2O: Calc, C, 63.81, H, 7.14, N, 9.92, F, 13.46. Found, C, 63.79, H, 7.30, N,
9.93, F, 13.31.
Step D: Preparation of Compound 1-7
Figure imgf000031_0001
To a solution of alcohol (5.73 kg, 99.9%, 20.28 mol) in dry THF (31.3 L), cooled to -20 °C, was added chloro diethylphosphate (3.79 kg, 21.29 mol). Lithium hexamethyldisilazide (1.35 M in THF; 31.5 L, 42.58 mol) was slowly added over 1.5 hours while maintaining the reaction temperature at -15 ± 3 °C. After stirring at 45°C for 2 hours, the HPLC assay confirmed complete conversion to pyrrolidine 1 7 (as a 80:20 transxis mixture).
The reaction mixture was quenched with water (50.6 L) at <15 °C and extracted with n-heptane (40.5 L) at 20 °C. The organic layer was washed with 10% aqueous NaCI solution (52 L). The organic layer was carefully extracted with 3 N HCl solution (40.6 L, 121.8 mol) with cooling to keep the temperature <35 °C. The aqueous layer (58 L) was adjusted to pH 11-12 with 50% aq NaOH (6.13 L, 116.1 mol) and extracted with n-heptane (54 L). The layers were separated. The organic layer was washed once with 10% aqueous NaCI solution (26 L) and the resulting heptane solution (48 kg total) was assayed \ by HPLC to contain cyclized nitrile L7 (as a 80:20 transxis mixture), which was used, as is, in the hydrolysis/epimerization reaction in Step E. Trans- Pyrrolidine Nitrile-HCl Salt lH-NMR (400.25 MHz, D2O) δ 7.42 (m, IH), 7.03-6.96 (om, 2H), 4,06-3.79 (om, 5H), 3.46 (bt, 7 = 11.6,
IH), 1.38 (s, 9H).
13C-NMR (100.65 MHz, D2O) δ 163.2 (dd, 7= 180.9, 12.6), 160.8 (dd, 7= 180.8, 12.7), 130.2 (dd, 7 =
10.2, 5.4), 116.9, 116.8, 112.1 (dd, 7 = 21.7, 3.4), 104.6 (t, 7 = 26.0), 63.2, 51.1, 49.3, 41.4, 32.3, 23.7 (3C). 19F-NMR (376.61 MHz, D2O) δ -109.87 (d, 7 = 7.7), -112.87 (d, 7 = 8.5).
MP (DSC): onset 179.23 °C, end 182.83 °C, peak 181.85 °C. HR-MS M+H theoretical 265.1516; found 265.1517.
Cis- Pyrrolidine Nitrile-HCl Salt lH-NMR (d4-CH3OH, 400.25 MHz) δ 7.57 (m, IH), 7.16-7.03 (om, 2H), 4.82 (s, OH), 4.20-4.08 (m, 2H),
4.07-3.90 (m, 3H), 3.89-3.76 (m, IH), 1.53 (s, 9H).
13C-NMR (d4-CH3OH, 100.65 MHz) δ 165.0 (dd, 7= 193.3, 12.5), 162.5 (dd, 7= 192.9, 12.5), 131.5, 118.9 (dd, 7= 14.3, 3.7), 118.3, 113.0 (dd, 7 = 21.7, 3.5), 105.4 (t, 7 = 26.2), 64.2, 51.8, 51.1, 40.2, 35.0, 24.9 (3C) 19F-NMR (376.61 MHz, d4-CH3OH) δ -111.29, -112.61 (d, 7 = 6.8).
MP (DSC): onset 257.91 °C, end 263.37 °C, peak 262.15 °C.
Anal. Calcd for C15H19CIF2N2: Calc, C, 59.90, H, 6.37, N, 9.31, F, 12.63, Cl, 11.79. Found, C, 59.76, H, 6.26, N, 9.40, F, 12.54, Cl, 11.43.
Step E: Preparation of Compound 1-9
Figure imgf000032_0001
A solution of crude pyrrolidine nitrile 1 7 (4.88 kg, 18.46 mol) in n-heptane (-65 L total) from Step D was solvent-switched to ethanol (-20.6 L total) by distilling the n-heptane
(50-60 torr, 25 °C) down to about 6 L in volume, and adding ethanol (15 L). The resulting solution was concentrated to a 6 L volume, and diluted with ethanol (14.6 L) to give a total volume of 20.6 L. To this solution was added 50% aqueous NaOH (2.7 L, 51.15 mol) over 2 minutes with stirring. This mixture was then heated to reflux (78-80 °C) under nitrogen for 5 to 6 hours. The reaction was monitored by HPLC. After cooling to 20 °C, the reaction mixture was diluted with ethanol (25.4 L) and methanol (40.6 L) to give a total volume of -88 L (as a 1:1 MeOH:EtOH mixture). This solution was cooled to 12 °C and 96% H2SO4 (1.42 L, 25.6 mol) was added, while maintaining the temperature at about 20 °C. The slurry was filtered through a bed of Solka-Floc (5 kg) and anhydrous powder Na2SO4 (4 kg), and then washed with 1:1 EtOH:MeOH (60 L). The resulting filtrate was re-filtered, concentrated and solvent-switched to a 2-propanol solution (~15 L volume) by vacuum-distillation. The product crystallized during solvent switching.
The resulting slurry was heated to reflux (-80 °C) for 2 hours (which only partly dissolves product). The mixture was then allowed to cool. After cooling to 16 °C, MTBE (30.4 L, 3 volumes relative to IPA) was added to the mixture over 5 hours to give a 1:3 ratio of IPA:MTBE. After stirring at 16-17 °C for 3 days, the slurry was filtered, and the solids were washed with 12 L 1:3 IPA:MTBE. The solids were dried in vacuo (150 torr) at 50 °C, with a nitrogen sweep through the batch, for 3 days. Zwitterion IS was isolated as a white crystalline solid. Zwitterion IS assays: 99.97 LCAP; >99.99% e.e.. lH-NMR (400.25 MHz, D2O) δ 7.30 (m, IH), 6.92-6.85 (om, 2H), 4.68 (OH), 3.75-3.66 (om, 3H), 3.45
(bm, IH), 3.30-3.14 (om, 2H), 1.32 (s, 9H).
13C-NMR (100.65 MHz, D2O) δ 176.5, 162.8 (dd, 7= 123.7, 12.6), 160.3 (dd, 7= 124.5, 12.7), 129.9 (dd, 7= 10.1, 5.9), 119.7, 111.7 (dd, 7 = 21.5, 3.6), 104.1 (t, 7 = 26.2), 62.0, 51.9, 51.0, 50.6, 41.3, 23.7 (3C). MP (DSC): onset 215 °C, peak 217 °C . Anal. Calcd for C15H19F2NO2: Calc, C, 63.59; H, 6.76; F, 13.41; N, 4.94. Found, C, 63.50; H, 6.81; F,
13.11; N, 4.91.
Preparation of (3S,4R)-l-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidine-3-carboxamide (1-8).
An analytical sample of the trans amide intermediate 1-8 was prepared from acid 1-9, via the acid chloride and quenching with ammonium hydroxide: IH NMR (CDCI3) δ 7.28 (m, IH), 6.84-6.73 (om, 2H),
6.60 (br s, IH), 5.92 (br s, IH), 3.67 (m, IH), 3.26 (t, 7= 8.7, IH), 3.08 (dd, 7 = 9.2, 4.2, IH), 2.98 (t, 7 = 8.3, lH), 2.87 (m, 1H), 2.61 (t, 78.5, IH), 1.11 (s, 9H); 13c NMR (CDCl3) δ 177.8, 161.7 (dd, 7 = 248.4, 12.9), 160.7 (dd, 7 = 248.6, 12.0), 129.8 (dd, 7 = 9.4, 6.4), 126.1 (dd,7= 14.1, 3.6), 111.4 (dd, 7 = 20.9, 3.6), 104.0 (q, 7= 51.8), 53.2, 52.4, 51.2, 50.4, 41.5, 26.1 (3C). Anal. Calcd for C15H20F2N2O: C, 63.81, H, 7.14, N,
9.92, F, 13.46, O 5.67. Found, C, 63.72, H, 7.00, N, 9.89, F, 13.91.
EXAMPLE 2
Figure imgf000034_0001
Compound 2 was prepared from 2-chloroacetophenone (Aldrich) following a similar procedure to that described for compound 1^9 . lH-NMR (400.25 MHz, CD3OD) δ 7.40 (m, 2H), 7.34 (m, 2H), 7.26 (m, IH), 3.85 (m, IH), 3.80-3.70 (m,
2H), 3.58 (br t, 7=10.5, IH), 3.31 (m, IH), 3.16 (dd, 7= 18.8, 9.6, IH), 1.43 (s, 9H). 13C-NMR (100.65 MHz, CD3OD) δ 175.5, 138.0, 128.4, 127.3, 127.2, 61.1, 53.7, 52.3, 51.9, 47.4, 23.5. HR-MS M+H theoretical 248.1651; found 248.1649.
Figure imgf000034_0002
Compound 3 was prepared from 4'-methoxy-2-bromoacetophenone (Aldrich) following a similar procedure to that described for compound 1-9. lH-NMR (400.25 MHz, CD3OD) δ 7.31 (d, 7 = 8.7, 2H), 6.88 (d, 7 = 8.7, 2H), 4.89 (OH), 3.79-3.68 (om,
3H), 3.76 (s, 3H), 3.55 (brt, 7= 10.6, IH), 3.25 (brt, 7=11.2, IH), 3.11 (dd, 7= 18.8, 10.0, IH), 1.41 (s, 9H). 13C-NMR (100.65 MHz, CD3OD) δ 177.2, 160.7, 131.3, 129.9, 115.4, 62.6, 55.9, 55.2, 54.1, 53.3, 48.5,
25.0. HR-MS M+H theoretical 278.1756; found 278.1754.

Claims

WHAT IS CLAIMED IS:
A process for the preparation of compounds of structural formula (I):
Figure imgf000035_0001
(I)
wherein
Rl is selected from the group consisting of
(1) hydrogen,
(2) amidino, (3) Ci-4 alkyliminoyl,
(4) Ci -10 alkyl,
(5) -(CH2)n-C3-7 cycloalkyl,
(6) -(CH2)n-phenyl,
(7) -(CH2)n-naphthyl, and (8) -(CH2)n-heteroaryl, in which phenyl, naphthyl, and heteroaryl are unsubstituted or substituted with one to three groups independently selected from R3; and alkyl, cycloalkyl, and (CH2)n are unsubstituted or substituted with one to three groups independently selected fromR3 and oxo;
is selected from the group consisting of
(1) Ci-4 alkyl,
(2) -(CH2)n-cycloalkyl,
(3) -(CH2)n-heterocycloalkyl,
(4) -(CH2)n-phenyl,
(5) -(CH2)n-naphthyl, and
(6) -(CH2)n-heteroaryl wherein heteroaryl is selected from the group consisting of
(1) pyridinyl,
(2) furyl,
(3) thienyl,
(4) pyrrolyl,
(5) oxazolyl, (6) thiazolyl,
(7) imidazolyl,
(8) pyrazolyl,
(9) isoxazolyl, (10) isothiazolyl,
(11) pyrimidinyl,
(12) pyrazinyl,
(13) pyridazinyl,
(14) quinolyl, (15) isoquinolyl,
(16) benzimidazolyl,
(17) benzofuryl,
(18) benzothienyl,
(19) indolyl, (20) benzthiazolyl, and
(21) benzoxazolyl; in which alkyl, phenyl, naphthyl, heteroaryl, and (CH2)n are unsubstituted or substituted with one to three groups independently selected from R3;
each R is independently selected from the group consisting of
(1) Ci-6 alkyl,
(2) -(CH2)n-phenyl,
(3) -(CH2)n-naphthyl,
(4) -(CH2)n-heteroaryl, (5) -(CH2)n-heterocycloalkyl,
(6) -(CH2)nC3-7 cycloalkyl,
(7) halogen,
(8) OR4,
Figure imgf000036_0001
(10) NO2,
(11) -(CH2)nNR4S02R4,
(12) -(CH2)nS02N(R4)2,
(13) -(CH2)nS(0)pR4
(14) CF3, (15) CH2CF3,
(16) OCF , and (17) OCH2CF3; in which heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, oxo, Cι_4 alkyl, trifluoromethyl, and Cι_4 alkoxy; and wherein any methylene (CH2) carbon atom in R is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Ci-4 alkyl; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
each R4 is independently selected from the group consisting of (1) hydrogen,
(2) C1-6 alkyl,
(3) -(CH2)n-phenyl,
(4) -(CH2)n-heteroaryl,
(5) -(CH2)n-naphthyl, (6) -(CH2)n-heterocycloalkyl,
(7) -(CH2)nC3-7 cycloalkyl, and
(8) -(CH2)nC3-7 bicycloalkyl; wherein alkyl, phenyl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with one to three groups independently selected from halogen, Cl-4 alkyl, hydroxy, and Ci-4 alkoxy; or two R4 groups together with the atom to which they are attached form a 4- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and NCi-4 alkyl; and n is 0, 1, 2, 3 or 4;
comprising the steps of: (a) preparing an alcohol of structural formula (V)
Figure imgf000037_0001
wherein
X is bromide or chloride, and R^ is as defined above, by treating a ketone of structural formula (IV),
O
X R2 CV) wherein X is bromide or chloride, and R2 is as defined above, with a reducing agent, and isolating the resulting product;
(b) forming an amino alcohol of structural formula (VII)
QH H
M. T
(VII)
wherein Rl and R2 are as defined above, by treating the alcohol of structural formula (V) with an amine of general formula RINH2, wherein Rl is as defined above, and a base in a solvent, and isolating the resulting product;
(c) forming a compound of structural formula (VET)
Y QH
(Vlll)
wherein Y is -CN or -Cθ2R^ and R5 is Cι_4 alkyl, and wherein Rl and R2 are as defined above, by treating the amino alcohol of structural formula (VII) with a compound of general formula (XI)
(XI),
wherein Y is -CN or -Cθ2R^. and R is Ci-4 alkyl, and isolating the resulting product;
(d) forming a pyrrolidine compound of structural formula (X)
Figure imgf000038_0001
(X)
wherein Y, Rl and R2 are as defined above, by treating the compound of structural formula (VIII) with an alcohol activating reagent, followed by a base; (e) forming a trans-pyrrolidine acid of structural formula (I)
Figure imgf000039_0001
(I)
wherein R and R are as defined above, by hydrolyzing the pyrrolidine compound of structural formula (X) with an aqueous base in a solvent; and
(f) isolating the resulting product.
2. The process.of Claim 1 wherein the reducing agent used to treat compound of formula (TV) of step (a) is (+)-DH° chloride.
3. The process of Claim 1 wherein the compound of formula (TV) of step (a) is treated with a reducing agent selected from the group consisting of borane-N,N-diethyl aniline, borane-THF, and borane-dimethylsulfide, in the presence of a catalyst.
4. The process of Claim 3 wherein the reducing agent is borane-N,N-diethyl aniline.
5. The process of Claim 4 wherein the catalyst selected from the group consisting of (S)-CBS and (S)-2-methyl CBS oxazaborolidine.
6. The process of Claim 5 wherein the catalyst is (S)-2-methyl CBS oxazaborolidine.
7. The process of Claim 1 wherein the alcohol of formula (V) is treated with an amine of general formula RINH2, wherein Rl is selected from the group consisting of hydrogen, -(CH2)nphenyl> and Ci-6alkyl.
8. The process of Claim 7 wherein Rl is tert-butyl.
9. The process of Claim 1 wherein the alcohol of formula (V) is treated with a base selected from the group consisting of NaOH, LiOH, and KOH.
10. The process of Claim 9 wherein the base is NaOH.
11. The process of Claim 1 wherein, the compound of formula (XI) is the compound wherein Y is -CN.
12. The process of Claim 11 wherein the compound of formula (Vffl) is formed by adding a 1:1 mixture of ethanohformamide.
13. The process of Claim 1 wherein the amino alcohol of formula (VITf) is treated with an alcohol activating reagent selected from the group consisting of C1P0(0R6)2, C1P0(N(R6)2)2> MsCl, Ms2θ, TsCl, and Ts2θ, wherein R is Cι_4 alkyl or phenyl.
14. The process of Claim 13 wherein the alcohol activating reagent is chlorodiethyl phosphate.
15. The process of Claim 1 wherein amino alcohol of formula (VIII) is treated with a base selected from the group consisting of lithium hexamethyl disilazide, sodium hexamethyl disilazide, and potassium hexamethyldisilazide.
16. The process of Claim 15 wherein the base is lithium hexamethyl disilazide.
17. The process of Claim 1 wherein the pyrrolidine compound of formula (X) is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH.
18. The process of Claim 17 wherein the base is NaOH.
19. The process of Claim 1 wherein R is phenyl or thienyl optionally substituted with one to three groups independently selected from R3.
20. The process of Claim 19 wherein R2 is phenyl optionally substituted with one to three groups independently selected from R3.
21. The process of Claim 20 wherein R is selected from the group consisting of halogen, -CF3, and OR4, wherein R4 is as defined in Claim 1.
22. The process of Claim 21 wherein R2 is selected from the group of phenyl; ortho, jσαra-difluorophenyl; and α -α-methoxyphenyl.
23. The process of Claim 22 wherein R is ortho, pαrα-difluorophenyl.
24. The process of Claim 1 wherein the compound of structural formula (I) is isolated by forming a zwitterion of the trans pyrrolidine acid of structural formula (I)
Figure imgf000041_0001
(I)
wherein Rl and R2 are as defined above; recrystallizing the zwitterion from a solvent; and isolating the resulting product.
25. The process of Claim 24 wherein the zwitterion of the pyrrolidine acid of formula
(I) is formed at the isoelectric pH using an acid.
26. The process of Claim 25 wherein the acid is selected from sulfuric acid or hydrochloric acid.
27. The process of Claim 26 wherein the acid is sulfuric acid.
28. The process of Claim 24 wherein the zwitterion of the pyrrolidine acid of formula (I) is recrystallized from a solvent.
29. The process of Claim 28 wherein the solvent is selected from the group consisting of ethanol, isopropyl alcohol, methyl tert-butyl ether or a mixture thereof.
30. The process of Claim 29 wherein the solvent is a mixture of 1 :3 isopropyl alcohohmethyl tert-butyl ether.
31. The compound 1 -9
Figure imgf000042_0001
1-8
or a zwitterion or salt thereof.
32. The compound 2
Figure imgf000042_0002
or a zwitterion or salt thereof.
Figure imgf000042_0003
or a zwitterion or a salt thereof.
34. A process for the preparation of compounds of structural formula (I):
Figure imgf000042_0004
(I)
wherein
Rl is selected from the group consisting of
(1) hydrogen,
(2) amidino,
(3) Cι_4 alkyliminoy 1, (4) Ci-io alkyl,
(5) -(CH2)n-C3_7 cycloalkyl,
(6) -(CH2)n-phenyl,
(7) -(CH2)n-naphthyl, and (8) -(CH2)n-heteroaryl, in which phenyl, naphthyl, and heteroaryl are unsubstituted or substituted with one to three groups independently selected fromR3; and alkyl, cycloalkyl, and (CH2)n are unsubstituted or substituted with one to tliree groups independently selected from R3 and oxo;
R2 is selected from the group consisting of
(1) Ci-4 alkyl,
(2) -(CH2)n-cycloalkyl,
(3) -(CH2)n-heterocycloalkyl,
(4) -(CH2)n-phenyl,
(5) -(CH2)n-naphthyl, and
(6) -(CH2)n-heteroaryl wherein heteroaryl is selected from the group consisting of
(1) pyridinyl,
(2) furyl,
(3) thienyl,
(4) pyrrolyl,
(5) oxazolyl,
(6) thiazolyl,
(7) imidazolyl,
(8) pyrazolyl,
(9) isoxazolyl,
(10) isothiazolyl,
(11) pyrimidinyl,
(12) pyrazinyl,
(13) pyridazinyl,
(14) quinolyl,
(15) isoquinolyl,
(16) benzimidazolyl,
(17) benzofuryl,
(18) benzothienyl,
(19) indolyl, (20) benzthiazolyl, and
(21) benzoxazolyl; in which alkyl, phenyl, naphthyl, heteroaryl, and (CH2)n are unsubstituted or substituted with one to three groups independently selected from R ;
each R is independently selected from the group consisting of
(1) Ci-6 alkyl,
(2) -(CH2)n-phenyl,
(3) -(CH2)n-naphthyl, (4) -(CH2)n-heteroaryl,
(5) -(CH2)n-heterocycloalkyl,
(6) -(CH2)nC3-7 cycloalkyl,
(7) halogen,
(8) OR4, (9) -(CH )nN(R4)2,
(10) N02,
Figure imgf000044_0001
(12) -(CH2)nS02N(R4)2,
Figure imgf000044_0002
(14) CF3,
(15) CH2CF3,
(16) OCF3, and
(17) OCH2CF3; in which heteroaryl is as defined above; alkyl, phenyl, naphthyl, heteroaryl, cycloalkyl, and heterocycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, oxo, C -4 alkyl, trifluoromethyl, and Cι_4 alkoxy; and wherein any methylene (CH2) carbon atom in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cl- alkyl; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
each R is independently selected from the group consisting of
(1) hydrogen,
(2) C1-6 alkyl,
(3) -(CH2)n-phenyl, (4) -(CH2)n-heteroaryl,
(5) -(CH2)n-naphthyl, (6) -(CH2)n-heterocycloalkyl,
(7) -(CH2)nC3-7 cycloalkyl, and
(8) -(CH2)nC3-7 bicycloalkyl; wherein alkyl, phenyl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with one to three groups independently selected from halogen, Ci- | alkyl, hydroxy, and Ci-4 alkoxy; or two R groups together with the atom to which they are attached form a 4- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and NCχ.4 alkyl; and is 0, 1, 2, 3 or 4;
comprising the steps of:
(a) hydrolyzing a pyrrolidine compound of structural formula (X), wherein Y, Rl and R2 are as defined above,
Figure imgf000045_0001
(X)
with an aqueous base in a solvent; and
(b) isolating the resulting product.
35. The process of Claim 34 wherein the pyrrolidine compound of formula (X) is hydrolyzed with a base selected from the group consisting of NaOH, LiOH and KOH.
36. The process of Claim 35 wherein the base is aqueous NaOH.
37. The process of Claim 36 wherein R is selected from the group of phenyl; ortho, pαr -difluorophenyl; and pαrα-methoxyphenyl.
38. The process of Claim 37 wherein R is ortho, pαra-difluorophenyl.
PCT/US2004/011253 2003-04-14 2004-04-09 Process and intermediates for the preparation of pyrrolidine carboxylic acids WO2004092126A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04750027A EP1615882A2 (en) 2003-04-14 2004-04-09 Process and intermediates for the preparation of pyrrolidine carboxylic acids
CA002521487A CA2521487A1 (en) 2003-04-14 2004-04-09 Process and intermediates for the preparation of pyrrolidine carboxylic acids
JP2006509940A JP2006523700A (en) 2003-04-14 2004-04-09 Methods and intermediates for the preparation of pyrrolidinecarboxylic acids
US10/550,640 US20060199958A1 (en) 2003-04-14 2004-04-09 Process and intermediates for the preparation of pyrrolidine carboxylic acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46279503P 2003-04-14 2003-04-14
US60/462,795 2003-04-14

Publications (3)

Publication Number Publication Date
WO2004092126A2 true WO2004092126A2 (en) 2004-10-28
WO2004092126A3 WO2004092126A3 (en) 2005-01-20
WO2004092126B1 WO2004092126B1 (en) 2005-03-31

Family

ID=33299992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011253 WO2004092126A2 (en) 2003-04-14 2004-04-09 Process and intermediates for the preparation of pyrrolidine carboxylic acids

Country Status (8)

Country Link
US (1) US20060199958A1 (en)
EP (1) EP1615882A2 (en)
JP (1) JP2006523700A (en)
CN (1) CN1774419A (en)
AR (1) AR044510A1 (en)
CA (1) CA2521487A1 (en)
TW (1) TW200504011A (en)
WO (1) WO2004092126A2 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123762A1 (en) * 2005-05-16 2006-11-23 Sumitomo Chemical Company, Limited Process for production of pyrrolidine compounds
WO2009037306A2 (en) * 2007-09-21 2009-03-26 Basf Se Accelerated amide and ester reductions with amine boranes and additives
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
WO2010119848A1 (en) 2009-04-14 2010-10-21 アステラス製薬株式会社 Novel method for producing optically active pyrrolidine compound
CN104695023A (en) * 2015-02-14 2015-06-10 河北科技大学 Tetrahydro pyrrole monohydrate-2-carboxylic acid monocrystal and preparation method thereof
US9879018B2 (en) 2015-10-16 2018-01-30 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2021091283A1 (en) 2019-11-07 2021-05-14 Lg Chem, Ltd. Melanocortin-4 receptor agonists
WO2022092914A1 (en) 2020-10-29 2022-05-05 주식회사 엘지화학 Crystal form iv of melanocortin receptor agonist compound, and preparation method therefor
WO2022092909A1 (en) 2020-10-29 2022-05-05 주식회사 엘지화학 Crystalline form i of melanocortin receptor agonist compound, and method for preparing same
WO2022092908A1 (en) 2020-10-29 2022-05-05 주식회사 엘지화학 Amorphous melanocortin-4 receptor agonist
WO2022092910A1 (en) 2020-10-29 2022-05-05 주식회사 엘지화학 Crystal type ii of malanocortin receptor agonist compound and method for preparing same
WO2022092913A1 (en) 2020-10-29 2022-05-05 주식회사 엘지화학 Crystalline form iii of melanocortin receptor agonist compound and method for preparing same
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2022139444A1 (en) 2020-12-22 2022-06-30 주식회사 엘지화학 Crystal type ii of melanocortin receptor agonist compound and method for preparing same
WO2022139443A1 (en) 2020-12-22 2022-06-30 주식회사 엘지화학 Crystalline form i of melanocortin receptor agonist compound and method for preparing same
WO2022139441A1 (en) 2020-12-22 2022-06-30 주식회사 엘지화학 Amorphous melanocortin receptor agonist and method for preparing same
WO2022139446A1 (en) 2020-12-22 2022-06-30 주식회사 엘지화학 Crystalline form iii of melanocortin receptor agonist compound and preparation method therefor
WO2022182194A1 (en) 2021-02-26 2022-09-01 주식회사 엘지화학 Melanocortin-4 receptor agonist
WO2022235104A1 (en) 2021-05-06 2022-11-10 주식회사 엘지화학 Crystalline form v of melanocortin receptor agonist compound, and method for preparing same
WO2022235106A1 (en) 2021-05-07 2022-11-10 주식회사 엘지화학 Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof
WO2022235107A1 (en) 2021-05-07 2022-11-10 주식회사 엘지화학 Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same
WO2022235105A1 (en) 2021-05-06 2022-11-10 주식회사 엘지화학 Crystal form vii of melanocortin receptor agonist compound and method for preparing same
WO2022235103A1 (en) 2021-05-07 2022-11-10 주식회사 엘지화학 Sulfate crystals of melanocortin receptor agonist compound and method of producing same
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057933A1 (en) * 1997-06-17 1998-12-23 Abbott Laboratories Pyrrolidine carboxylic acid derivatives as endothelin antagonists
WO2002068388A2 (en) * 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002068387A2 (en) * 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057933A1 (en) * 1997-06-17 1998-12-23 Abbott Laboratories Pyrrolidine carboxylic acid derivatives as endothelin antagonists
WO2002068388A2 (en) * 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002068387A2 (en) * 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
WO2006123762A1 (en) * 2005-05-16 2006-11-23 Sumitomo Chemical Company, Limited Process for production of pyrrolidine compounds
WO2009037306A2 (en) * 2007-09-21 2009-03-26 Basf Se Accelerated amide and ester reductions with amine boranes and additives
WO2009037306A3 (en) * 2007-09-21 2009-11-12 Basf Se Accelerated amide and ester reductions with amine boranes and additives
CN101801897A (en) * 2007-09-21 2010-08-11 巴斯夫欧洲公司 Promote acid amides and ester reduction with amine borine and additive
US8013189B2 (en) 2007-09-21 2011-09-06 Basf Se Accelerated amide and ester reductions with amine boranes and additives
WO2010119848A1 (en) 2009-04-14 2010-10-21 アステラス製薬株式会社 Novel method for producing optically active pyrrolidine compound
EP2420487A1 (en) * 2009-04-14 2012-02-22 Astellas Pharma Inc. Novel method for producing optically active pyrrolidine compound
EP2420487A4 (en) * 2009-04-14 2012-10-17 Astellas Pharma Inc Novel method for producing optically active pyrrolidine compound
CN104695023A (en) * 2015-02-14 2015-06-10 河北科技大学 Tetrahydro pyrrole monohydrate-2-carboxylic acid monocrystal and preparation method thereof
CN104695023B (en) * 2015-02-14 2017-02-01 河北科技大学 Tetrahydro pyrrole monohydrate-2-carboxylic acid monocrystal and preparation method thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11535626B2 (en) 2015-10-16 2022-12-27 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof
US9951080B2 (en) 2015-10-16 2018-04-24 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US9963459B1 (en) 2015-10-16 2018-05-08 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof
US10017517B2 (en) 2015-10-16 2018-07-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluorethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10202394B2 (en) 2015-10-16 2019-02-12 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10202393B2 (en) 2015-10-16 2019-02-12 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10344036B2 (en) 2015-10-16 2019-07-09 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof
US10519164B2 (en) 2015-10-16 2019-12-31 Abbvie Inc. Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10597400B2 (en) 2015-10-16 2020-03-24 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
US10730883B2 (en) 2015-10-16 2020-08-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10981924B2 (en) 2015-10-16 2021-04-20 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10981923B2 (en) 2015-10-16 2021-04-20 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10995095B2 (en) 2015-10-16 2021-05-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
US11993606B2 (en) 2015-10-16 2024-05-28 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11186584B2 (en) 2015-10-16 2021-11-30 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11198697B1 (en) 2015-10-16 2021-12-14 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11993605B2 (en) 2015-10-16 2024-05-28 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11976077B2 (en) 2015-10-16 2024-05-07 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof
US11795175B2 (en) 2015-10-16 2023-10-24 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11787815B1 (en) 2015-10-16 2023-10-17 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780847B1 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773105B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11767326B2 (en) 2015-10-16 2023-09-26 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11718627B2 (en) 2015-10-16 2023-08-08 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11680069B2 (en) 2015-10-16 2023-06-20 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11661425B2 (en) 2015-10-16 2023-05-30 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11535625B2 (en) 2015-10-16 2022-12-27 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US9879019B2 (en) 2015-10-16 2018-01-30 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11535624B2 (en) 2015-10-16 2022-12-27 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US9879018B2 (en) 2015-10-16 2018-01-30 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl and solid state forms thereof
WO2021091283A1 (en) 2019-11-07 2021-05-14 Lg Chem, Ltd. Melanocortin-4 receptor agonists
WO2022092913A1 (en) 2020-10-29 2022-05-05 주식회사 엘지화학 Crystalline form iii of melanocortin receptor agonist compound and method for preparing same
WO2022092914A1 (en) 2020-10-29 2022-05-05 주식회사 엘지화학 Crystal form iv of melanocortin receptor agonist compound, and preparation method therefor
WO2022092909A1 (en) 2020-10-29 2022-05-05 주식회사 엘지화학 Crystalline form i of melanocortin receptor agonist compound, and method for preparing same
WO2022092908A1 (en) 2020-10-29 2022-05-05 주식회사 엘지화학 Amorphous melanocortin-4 receptor agonist
WO2022092910A1 (en) 2020-10-29 2022-05-05 주식회사 엘지화학 Crystal type ii of malanocortin receptor agonist compound and method for preparing same
WO2022139443A1 (en) 2020-12-22 2022-06-30 주식회사 엘지화학 Crystalline form i of melanocortin receptor agonist compound and method for preparing same
WO2022139441A1 (en) 2020-12-22 2022-06-30 주식회사 엘지화학 Amorphous melanocortin receptor agonist and method for preparing same
WO2022139444A1 (en) 2020-12-22 2022-06-30 주식회사 엘지화학 Crystal type ii of melanocortin receptor agonist compound and method for preparing same
WO2022139446A1 (en) 2020-12-22 2022-06-30 주식회사 엘지화학 Crystalline form iii of melanocortin receptor agonist compound and preparation method therefor
WO2022182194A1 (en) 2021-02-26 2022-09-01 주식회사 엘지화학 Melanocortin-4 receptor agonist
WO2022235104A1 (en) 2021-05-06 2022-11-10 주식회사 엘지화학 Crystalline form v of melanocortin receptor agonist compound, and method for preparing same
WO2022235105A1 (en) 2021-05-06 2022-11-10 주식회사 엘지화학 Crystal form vii of melanocortin receptor agonist compound and method for preparing same
WO2022235103A1 (en) 2021-05-07 2022-11-10 주식회사 엘지화학 Sulfate crystals of melanocortin receptor agonist compound and method of producing same
WO2022235106A1 (en) 2021-05-07 2022-11-10 주식회사 엘지화학 Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof
WO2022235107A1 (en) 2021-05-07 2022-11-10 주식회사 엘지화학 Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same

Also Published As

Publication number Publication date
US20060199958A1 (en) 2006-09-07
EP1615882A2 (en) 2006-01-18
AR044510A1 (en) 2005-09-14
CA2521487A1 (en) 2004-10-28
CN1774419A (en) 2006-05-17
JP2006523700A (en) 2006-10-19
TW200504011A (en) 2005-02-01
WO2004092126A3 (en) 2005-01-20
WO2004092126B1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
WO2004092126A2 (en) Process and intermediates for the preparation of pyrrolidine carboxylic acids
JP7051970B2 (en) Method for producing a compound having PDE4 inhibitory activity
KR102630456B1 (en) Method of manufacturing brivaracetam
KR100284216B1 (en) Asymmetric Preparation of Florfenicol, Thiamphenicol, Chloramphenicol and Oxazoline Intermediates
JP2008534657A (en) Intermediate compound for the preparation of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H-dibenz [2,3: 6,7] -oxepino [4,5-c] pyrrole
US8207352B2 (en) Process for the manufacture of enantiomerically pure antifungal azoles as ravuconazole and isavuconazole
CA2930870C (en) Processes for the preparation of pyrimidinylcyclopentane compounds
JP2010532356A (en) Methods and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2020094434A1 (en) Process for preparation of optically enriched isoxazolines
US7223867B2 (en) Preparation of benzosuberonylpiperidine compounds
JP2015003908A (en) Hydroxyproline derivative
EP1340743A1 (en) Optically active amine derivative and method of synthesis
JP2004526797A (en) Method for producing 2- [5- (4-fluorophenyl) -3-pyridylmethylaminomethyl] chroman
WO2006062890A1 (en) Method of making imidazole-2-thiones
KR101686087B1 (en) Process for Production of Optically Active Indoline Derivatives or Salts Thereof
KR0136706B1 (en) Process for 3-amino pyrrolidine derivatives
US5710283A (en) Preparation of chiral pyrrolidinone derivatives
WO1994006766A1 (en) Chiral quinolone intermediates
KR100850558B1 (en) Process for preparing useful in synthesis of atorvastatin
JPS63503384A (en) Effective stereoconservative synthesis of 1-substituted (S)- and (R)-2-aminomethylpyrrolidines and their intermediates
JPWO2007037303A1 (en) Process for producing tetra-substituted-5-azaspiro [2.4] heptane derivative and optically active intermediate thereof
JP2024502364A (en) Method for producing pyrrolopyridine derivatives
KR100424393B1 (en) Process for the preparation of oxiracetam
KR20230158354A (en) New Method for preparing Edoxaban intermediate, and the method for preparing Edoxaban using thereof
TW201920132A (en) New compound useful in the manufacture of medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20041119

WWE Wipo information: entry into national phase

Ref document number: 10550640

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2521487

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 4613/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006509940

Country of ref document: JP

Ref document number: 20048098822

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004750027

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004750027

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004750027

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10550640

Country of ref document: US